CA2256464A1 - Tumor necrosis factor-related polypeptide - Google Patents
Tumor necrosis factor-related polypeptide Download PDFInfo
- Publication number
- CA2256464A1 CA2256464A1 CA002256464A CA2256464A CA2256464A1 CA 2256464 A1 CA2256464 A1 CA 2256464A1 CA 002256464 A CA002256464 A CA 002256464A CA 2256464 A CA2256464 A CA 2256464A CA 2256464 A1 CA2256464 A1 CA 2256464A1
- Authority
- CA
- Canada
- Prior art keywords
- agp
- seq
- polypeptide
- nucleic acid
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 48
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 48
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 45
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title abstract description 20
- 102000003390 tumor necrosis factor Human genes 0.000 title abstract description 5
- 101710186701 Alpha-1-acid glycoprotein 1 Proteins 0.000 claims abstract description 138
- 102100022463 Alpha-1-acid glycoprotein 1 Human genes 0.000 claims abstract description 137
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 35
- 230000014509 gene expression Effects 0.000 claims abstract description 26
- 239000005557 antagonist Substances 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 66
- 102000039446 nucleic acids Human genes 0.000 claims description 66
- 239000002299 complementary DNA Substances 0.000 claims description 40
- 108020004414 DNA Proteins 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 230000004071 biological effect Effects 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 210000000988 bone and bone Anatomy 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 208000020084 Bone disease Diseases 0.000 claims description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000000646 Interleukin-3 Human genes 0.000 claims description 3
- 108010002386 Interleukin-3 Proteins 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 229920003169 water-soluble polymer Polymers 0.000 claims description 3
- 229940122361 Bisphosphonate Drugs 0.000 claims description 2
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 claims description 2
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 150000004663 bisphosphonates Chemical class 0.000 claims description 2
- 230000008468 bone growth Effects 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 230000000921 morphogenic effect Effects 0.000 claims description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 2
- 239000000199 parathyroid hormone Substances 0.000 claims description 2
- 229960001319 parathyroid hormone Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102100020880 Kit ligand Human genes 0.000 claims 1
- 101710177504 Kit ligand Proteins 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- 102100034195 Thrombopoietin Human genes 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 18
- 206010061218 Inflammation Diseases 0.000 abstract description 14
- 230000004054 inflammatory process Effects 0.000 abstract description 14
- 208000006386 Bone Resorption Diseases 0.000 abstract description 11
- 230000024279 bone resorption Effects 0.000 abstract description 11
- 239000013598 vector Substances 0.000 abstract description 8
- 206010028851 Necrosis Diseases 0.000 abstract description 7
- 230000017074 necrotic cell death Effects 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 4
- 238000011830 transgenic mouse model Methods 0.000 description 35
- 230000009261 transgenic effect Effects 0.000 description 31
- 241000699660 Mus musculus Species 0.000 description 30
- 102100040247 Tumor necrosis factor Human genes 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 241001529936 Murinae Species 0.000 description 16
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 14
- 210000001185 bone marrow Anatomy 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 8
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 8
- 108700019146 Transgenes Proteins 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 206010020718 hyperplasia Diseases 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000002997 osteoclast Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 5
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- OPEPUCYIGFEGSW-WDSKDSINSA-N Asn-Gly-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OPEPUCYIGFEGSW-WDSKDSINSA-N 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010039471 Fas Ligand Protein Proteins 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101150073396 LTA gene Proteins 0.000 description 4
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 4
- 108010062166 Lys-Asn-Asp Proteins 0.000 description 4
- 102000003896 Myeloperoxidases Human genes 0.000 description 4
- 108090000235 Myeloperoxidases Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- JHSRGEODDALISP-XVSYOHENSA-N Phe-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JHSRGEODDALISP-XVSYOHENSA-N 0.000 description 4
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000000013 bile duct Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 108010078144 glutaminyl-glycine Proteins 0.000 description 4
- 108010028188 glycyl-histidyl-serine Proteins 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 108010017391 lysylvaline Proteins 0.000 description 4
- 108010085203 methionylmethionine Proteins 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108010072637 phenylalanyl-arginyl-phenylalanine Proteins 0.000 description 4
- 108010084525 phenylalanyl-phenylalanyl-glycine Proteins 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 3
- ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 3
- AMIQZQAAYGYKOP-FXQIFTODSA-N Arg-Ser-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O AMIQZQAAYGYKOP-FXQIFTODSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- XKPACHRGOWQHFH-IRIUXVKKSA-N Gln-Thr-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XKPACHRGOWQHFH-IRIUXVKKSA-N 0.000 description 3
- MXOODARRORARSU-ACZMJKKPSA-N Glu-Ala-Ser Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N MXOODARRORARSU-ACZMJKKPSA-N 0.000 description 3
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 3
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 3
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- IBSGMIPRBMPMHE-IHRRRGAJSA-N Leu-Met-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(O)=O IBSGMIPRBMPMHE-IHRRRGAJSA-N 0.000 description 3
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 3
- GNUCSNWOCQFMMC-UFYCRDLUSA-N Phe-Arg-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 GNUCSNWOCQFMMC-UFYCRDLUSA-N 0.000 description 3
- IWZRODDWOSIXPZ-IRXDYDNUSA-N Phe-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=CC=C1 IWZRODDWOSIXPZ-IRXDYDNUSA-N 0.000 description 3
- FIXILCYTSAUERA-FXQIFTODSA-N Ser-Ala-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FIXILCYTSAUERA-FXQIFTODSA-N 0.000 description 3
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 3
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 description 3
- SDFUZKIAHWRUCS-QEJZJMRPSA-N Ser-Trp-Glu Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CO)N SDFUZKIAHWRUCS-QEJZJMRPSA-N 0.000 description 3
- 206010041660 Splenomegaly Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000001919 adrenal effect Effects 0.000 description 3
- 108010008355 arginyl-glutamine Proteins 0.000 description 3
- 108010062796 arginyllysine Proteins 0.000 description 3
- 108010093581 aspartyl-proline Proteins 0.000 description 3
- 108010038633 aspartylglutamate Proteins 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000002962 histologic effect Effects 0.000 description 3
- 108010034529 leucyl-lysine Proteins 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000000849 parathyroid Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000001625 seminal vesicle Anatomy 0.000 description 3
- 108010026333 seryl-proline Proteins 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 201000010653 vesiculitis Diseases 0.000 description 3
- -1 4-lBB Proteins 0.000 description 2
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- JJGRJMKUOYXZRA-LPEHRKFASA-N Asn-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N)C(=O)O JJGRJMKUOYXZRA-LPEHRKFASA-N 0.000 description 2
- QISZHYWZHJRDAO-CIUDSAMLSA-N Asn-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N QISZHYWZHJRDAO-CIUDSAMLSA-N 0.000 description 2
- OGMDXNFGPOPZTK-GUBZILKMSA-N Asn-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N OGMDXNFGPOPZTK-GUBZILKMSA-N 0.000 description 2
- KYQJHBWHRASMKG-ZLUOBGJFSA-N Asn-Ser-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O KYQJHBWHRASMKG-ZLUOBGJFSA-N 0.000 description 2
- PUUPMDXIHCOPJU-HJGDQZAQSA-N Asn-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O PUUPMDXIHCOPJU-HJGDQZAQSA-N 0.000 description 2
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 2
- RYEWQKQXRJCHIO-SRVKXCTJSA-N Asp-Asn-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 RYEWQKQXRJCHIO-SRVKXCTJSA-N 0.000 description 2
- RXBGWGRSWXOBGK-KKUMJFAQSA-N Asp-Lys-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RXBGWGRSWXOBGK-KKUMJFAQSA-N 0.000 description 2
- KBJVTFWQWXCYCQ-IUKAMOBKSA-N Asp-Thr-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KBJVTFWQWXCYCQ-IUKAMOBKSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- PDRMRVHPAQKTLT-NAKRPEOUSA-N Cys-Ile-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O PDRMRVHPAQKTLT-NAKRPEOUSA-N 0.000 description 2
- CHRCKSPMGYDLIA-SRVKXCTJSA-N Cys-Phe-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O CHRCKSPMGYDLIA-SRVKXCTJSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 2
- LGIKBBLQVSWUGK-DCAQKATOSA-N Gln-Leu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGIKBBLQVSWUGK-DCAQKATOSA-N 0.000 description 2
- PSERKXGRRADTKA-MNXVOIDGSA-N Gln-Leu-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PSERKXGRRADTKA-MNXVOIDGSA-N 0.000 description 2
- YPMDZWPZFOZYFG-GUBZILKMSA-N Gln-Leu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YPMDZWPZFOZYFG-GUBZILKMSA-N 0.000 description 2
- HSHCEAUPUPJPTE-JYJNAYRXSA-N Gln-Leu-Tyr Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HSHCEAUPUPJPTE-JYJNAYRXSA-N 0.000 description 2
- NMYFPKCIGUJMIK-GUBZILKMSA-N Gln-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N NMYFPKCIGUJMIK-GUBZILKMSA-N 0.000 description 2
- RWCBJYUPAUTWJD-NHCYSSNCSA-N Gln-Met-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O RWCBJYUPAUTWJD-NHCYSSNCSA-N 0.000 description 2
- XIYWAJQIWLXXAF-XKBZYTNZSA-N Gln-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O XIYWAJQIWLXXAF-XKBZYTNZSA-N 0.000 description 2
- AKDOUBMVLRCHBD-SIUGBPQLSA-N Gln-Tyr-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AKDOUBMVLRCHBD-SIUGBPQLSA-N 0.000 description 2
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 2
- QJCKNLPMTPXXEM-AUTRQRHGSA-N Glu-Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O QJCKNLPMTPXXEM-AUTRQRHGSA-N 0.000 description 2
- QXDXIXFSFHUYAX-MNXVOIDGSA-N Glu-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O QXDXIXFSFHUYAX-MNXVOIDGSA-N 0.000 description 2
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 2
- OCJRHJZKGGSPRW-IUCAKERBSA-N Glu-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O OCJRHJZKGGSPRW-IUCAKERBSA-N 0.000 description 2
- SOEPMWQCTJITPZ-SRVKXCTJSA-N Glu-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N SOEPMWQCTJITPZ-SRVKXCTJSA-N 0.000 description 2
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 2
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 2
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 2
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 2
- AFWYPMDMDYCKMD-KBPBESRZSA-N Gly-Leu-Tyr Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFWYPMDMDYCKMD-KBPBESRZSA-N 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- SKYULSWNBYAQMG-IHRRRGAJSA-N His-Leu-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SKYULSWNBYAQMG-IHRRRGAJSA-N 0.000 description 2
- ADDYYRVQQZFIMW-MNXVOIDGSA-N Ile-Lys-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ADDYYRVQQZFIMW-MNXVOIDGSA-N 0.000 description 2
- XQLGNKLSPYCRMZ-HJWJTTGWSA-N Ile-Phe-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)O)N XQLGNKLSPYCRMZ-HJWJTTGWSA-N 0.000 description 2
- ZUWSVOYKBCHLRR-MGHWNKPDSA-N Ile-Tyr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZUWSVOYKBCHLRR-MGHWNKPDSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- WCTCIIAGNMFYAO-DCAQKATOSA-N Leu-Cys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O WCTCIIAGNMFYAO-DCAQKATOSA-N 0.000 description 2
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 2
- BABSVXFGKFLIGW-UWVGGRQHSA-N Leu-Gly-Arg Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N BABSVXFGKFLIGW-UWVGGRQHSA-N 0.000 description 2
- KOSWSHVQIVTVQF-ZPFDUUQYSA-N Leu-Ile-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O KOSWSHVQIVTVQF-ZPFDUUQYSA-N 0.000 description 2
- RZXLZBIUTDQHJQ-SRVKXCTJSA-N Leu-Lys-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O RZXLZBIUTDQHJQ-SRVKXCTJSA-N 0.000 description 2
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 2
- GCXGCIYIHXSKAY-ULQDDVLXSA-N Leu-Phe-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GCXGCIYIHXSKAY-ULQDDVLXSA-N 0.000 description 2
- QMKFDEUJGYNFMC-AVGNSLFASA-N Leu-Pro-Arg Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QMKFDEUJGYNFMC-AVGNSLFASA-N 0.000 description 2
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 2
- RZHLIPMZXOEJTL-AVGNSLFASA-N Lys-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)N RZHLIPMZXOEJTL-AVGNSLFASA-N 0.000 description 2
- KYNNSEJZFVCDIV-ZPFDUUQYSA-N Lys-Ile-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O KYNNSEJZFVCDIV-ZPFDUUQYSA-N 0.000 description 2
- GIKFNMZSGYAPEJ-HJGDQZAQSA-N Lys-Thr-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O GIKFNMZSGYAPEJ-HJGDQZAQSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- VTKPSXWRUGCOAC-GUBZILKMSA-N Met-Ala-Met Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCSC VTKPSXWRUGCOAC-GUBZILKMSA-N 0.000 description 2
- DRINJBAHUGXNFC-DCAQKATOSA-N Met-Asp-His Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O DRINJBAHUGXNFC-DCAQKATOSA-N 0.000 description 2
- OOSPRDCGTLQLBP-NHCYSSNCSA-N Met-Glu-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OOSPRDCGTLQLBP-NHCYSSNCSA-N 0.000 description 2
- NHXXGBXJTLRGJI-GUBZILKMSA-N Met-Pro-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NHXXGBXJTLRGJI-GUBZILKMSA-N 0.000 description 2
- KPVLLNDCBYXKNV-CYDGBPFRSA-N Met-Val-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KPVLLNDCBYXKNV-CYDGBPFRSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010029379 Neutrophilia Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- PLNHHOXNVSYKOB-JYJNAYRXSA-N Phe-Arg-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=CC=C1)N PLNHHOXNVSYKOB-JYJNAYRXSA-N 0.000 description 2
- KJJROSNFBRWPHS-JYJNAYRXSA-N Phe-Glu-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KJJROSNFBRWPHS-JYJNAYRXSA-N 0.000 description 2
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- LANQLYHLMYDWJP-SRVKXCTJSA-N Pro-Gln-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O LANQLYHLMYDWJP-SRVKXCTJSA-N 0.000 description 2
- VOZIBWWZSBIXQN-SRVKXCTJSA-N Pro-Glu-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O VOZIBWWZSBIXQN-SRVKXCTJSA-N 0.000 description 2
- AUQGUYPHJSMAKI-CYDGBPFRSA-N Pro-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 AUQGUYPHJSMAKI-CYDGBPFRSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 2
- DGHFNYXVIXNNMC-GUBZILKMSA-N Ser-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N DGHFNYXVIXNNMC-GUBZILKMSA-N 0.000 description 2
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 2
- IXCHOHLPHNGFTJ-YUMQZZPRSA-N Ser-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N IXCHOHLPHNGFTJ-YUMQZZPRSA-N 0.000 description 2
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 2
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 2
- PPNPDKGQRFSCAC-CIUDSAMLSA-N Ser-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPNPDKGQRFSCAC-CIUDSAMLSA-N 0.000 description 2
- LRWBCWGEUCKDTN-BJDJZHNGSA-N Ser-Lys-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LRWBCWGEUCKDTN-BJDJZHNGSA-N 0.000 description 2
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 2
- JLKWJWPDXPKKHI-FXQIFTODSA-N Ser-Pro-Asn Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CC(=O)N)C(=O)O JLKWJWPDXPKKHI-FXQIFTODSA-N 0.000 description 2
- BDMWLJLPPUCLNV-XGEHTFHBSA-N Ser-Thr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BDMWLJLPPUCLNV-XGEHTFHBSA-N 0.000 description 2
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 2
- TWLMXDWFVNEFFK-FJXKBIBVSA-N Thr-Arg-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O TWLMXDWFVNEFFK-FJXKBIBVSA-N 0.000 description 2
- JEDIEMIJYSRUBB-FOHZUACHSA-N Thr-Asp-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O JEDIEMIJYSRUBB-FOHZUACHSA-N 0.000 description 2
- AMXMBCAXAZUCFA-RHYQMDGZSA-N Thr-Leu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMXMBCAXAZUCFA-RHYQMDGZSA-N 0.000 description 2
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 2
- PZSDPRBZINDEJV-HTUGSXCWSA-N Thr-Phe-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PZSDPRBZINDEJV-HTUGSXCWSA-N 0.000 description 2
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 2
- BKVICMPZWRNWOC-RHYQMDGZSA-N Thr-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O BKVICMPZWRNWOC-RHYQMDGZSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- LTLBNCDNXQCOLB-UBHSHLNASA-N Trp-Asp-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 LTLBNCDNXQCOLB-UBHSHLNASA-N 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- RYSNTWVRSLCAJZ-RYUDHWBXSA-N Tyr-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RYSNTWVRSLCAJZ-RYUDHWBXSA-N 0.000 description 2
- KCPFDGNYAMKZQP-KBPBESRZSA-N Tyr-Gly-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O KCPFDGNYAMKZQP-KBPBESRZSA-N 0.000 description 2
- CNNVVEPJTFOGHI-ACRUOGEOSA-N Tyr-Lys-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CNNVVEPJTFOGHI-ACRUOGEOSA-N 0.000 description 2
- KZOZXAYPVKKDIO-UFYCRDLUSA-N Tyr-Met-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 KZOZXAYPVKKDIO-UFYCRDLUSA-N 0.000 description 2
- XJPXTYLVMUZGNW-IHRRRGAJSA-N Tyr-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O XJPXTYLVMUZGNW-IHRRRGAJSA-N 0.000 description 2
- QPOUERMDWKKZEG-HJPIBITLSA-N Tyr-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QPOUERMDWKKZEG-HJPIBITLSA-N 0.000 description 2
- WQOHKVRQDLNDIL-YJRXYDGGSA-N Tyr-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O WQOHKVRQDLNDIL-YJRXYDGGSA-N 0.000 description 2
- YKBUNNNRNZZUID-UFYCRDLUSA-N Tyr-Val-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YKBUNNNRNZZUID-UFYCRDLUSA-N 0.000 description 2
- DNOOLPROHJWCSQ-RCWTZXSCSA-N Val-Arg-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DNOOLPROHJWCSQ-RCWTZXSCSA-N 0.000 description 2
- AAOPYWQQBXHINJ-DZKIICNBSA-N Val-Gln-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N AAOPYWQQBXHINJ-DZKIICNBSA-N 0.000 description 2
- KNYHAWKHFQRYOX-PYJNHQTQSA-N Val-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N KNYHAWKHFQRYOX-PYJNHQTQSA-N 0.000 description 2
- APEBUJBRGCMMHP-HJWJTTGWSA-N Val-Ile-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 APEBUJBRGCMMHP-HJWJTTGWSA-N 0.000 description 2
- DAVNYIUELQBTAP-XUXIUFHCSA-N Val-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N DAVNYIUELQBTAP-XUXIUFHCSA-N 0.000 description 2
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 2
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 108010054812 diprotin A Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 2
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 2
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009716 hepatic expression Effects 0.000 description 2
- 108010025306 histidylleucine Proteins 0.000 description 2
- 108010092114 histidylphenylalanine Proteins 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 108010027338 isoleucylcysteine Proteins 0.000 description 2
- 231100000832 liver cell necrosis Toxicity 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000012753 partial hepatectomy Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DVWVZSJAYIJZFI-FXQIFTODSA-N Ala-Arg-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O DVWVZSJAYIJZFI-FXQIFTODSA-N 0.000 description 1
- IYCZBJXFSZSHPN-DLOVCJGASA-N Ala-Cys-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O IYCZBJXFSZSHPN-DLOVCJGASA-N 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- ROLXPVQSRCPVGK-XDTLVQLUSA-N Ala-Glu-Tyr Chemical compound N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O ROLXPVQSRCPVGK-XDTLVQLUSA-N 0.000 description 1
- JEPNLGMEZMCFEX-QSFUFRPTSA-N Ala-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C)N JEPNLGMEZMCFEX-QSFUFRPTSA-N 0.000 description 1
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 1
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- RWCLSUOSKWTXLA-FXQIFTODSA-N Arg-Asp-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RWCLSUOSKWTXLA-FXQIFTODSA-N 0.000 description 1
- VNFWDYWTSHFRRG-SRVKXCTJSA-N Arg-Gln-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O VNFWDYWTSHFRRG-SRVKXCTJSA-N 0.000 description 1
- QAODJPUKWNNNRP-DCAQKATOSA-N Arg-Glu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QAODJPUKWNNNRP-DCAQKATOSA-N 0.000 description 1
- OFIYLHVAAJYRBC-HJWJTTGWSA-N Arg-Ile-Phe Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O OFIYLHVAAJYRBC-HJWJTTGWSA-N 0.000 description 1
- NGTYEHIRESTSRX-UWVGGRQHSA-N Arg-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NGTYEHIRESTSRX-UWVGGRQHSA-N 0.000 description 1
- MTYLORHAQXVQOW-AVGNSLFASA-N Arg-Lys-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O MTYLORHAQXVQOW-AVGNSLFASA-N 0.000 description 1
- INOIAEUXVVNJKA-XGEHTFHBSA-N Arg-Thr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O INOIAEUXVVNJKA-XGEHTFHBSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- WVCJSDCHTUTONA-FXQIFTODSA-N Asn-Asp-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WVCJSDCHTUTONA-FXQIFTODSA-N 0.000 description 1
- BHQQRVARKXWXPP-ACZMJKKPSA-N Asn-Asp-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N BHQQRVARKXWXPP-ACZMJKKPSA-N 0.000 description 1
- UYXXMIZGHYKYAT-NHCYSSNCSA-N Asn-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)N)N UYXXMIZGHYKYAT-NHCYSSNCSA-N 0.000 description 1
- SEKBHZJLARBNPB-GHCJXIJMSA-N Asn-Ile-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O SEKBHZJLARBNPB-GHCJXIJMSA-N 0.000 description 1
- HPNDKUOLNRVRAY-BIIVOSGPSA-N Asn-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N)C(=O)O HPNDKUOLNRVRAY-BIIVOSGPSA-N 0.000 description 1
- HMQDRBKQMLRCCG-GMOBBJLQSA-N Asp-Arg-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HMQDRBKQMLRCCG-GMOBBJLQSA-N 0.000 description 1
- QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 description 1
- RYKWOUUZJFSJOH-FXQIFTODSA-N Asp-Gln-Glu Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N RYKWOUUZJFSJOH-FXQIFTODSA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- CMBDUPIBCOEWNE-BJDJZHNGSA-N Asp-Leu-Asp-Gln Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CMBDUPIBCOEWNE-BJDJZHNGSA-N 0.000 description 1
- MVRGBQGZSDJBSM-GMOBBJLQSA-N Asp-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)O)N MVRGBQGZSDJBSM-GMOBBJLQSA-N 0.000 description 1
- XYPJXLLXNSAWHZ-SRVKXCTJSA-N Asp-Ser-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XYPJXLLXNSAWHZ-SRVKXCTJSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- HKALUUKHYNEDRS-GUBZILKMSA-N Cys-Leu-Gln Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HKALUUKHYNEDRS-GUBZILKMSA-N 0.000 description 1
- RESAHOSBQHMOKH-KKUMJFAQSA-N Cys-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N RESAHOSBQHMOKH-KKUMJFAQSA-N 0.000 description 1
- XKDHARKYRGHLKO-QEJZJMRPSA-N Cys-Trp-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N XKDHARKYRGHLKO-QEJZJMRPSA-N 0.000 description 1
- SPJRFUJMDJGDRO-UBHSHLNASA-N Cys-Trp-Ser Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CS)N)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 SPJRFUJMDJGDRO-UBHSHLNASA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 description 1
- MCAVASRGVBVPMX-FXQIFTODSA-N Gln-Glu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MCAVASRGVBVPMX-FXQIFTODSA-N 0.000 description 1
- KCJJFESQRXGTGC-BQBZGAKWSA-N Gln-Glu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O KCJJFESQRXGTGC-BQBZGAKWSA-N 0.000 description 1
- HWEINOMSWQSJDC-SRVKXCTJSA-N Gln-Leu-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HWEINOMSWQSJDC-SRVKXCTJSA-N 0.000 description 1
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 1
- LURQDGKYBFWWJA-MNXVOIDGSA-N Gln-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N LURQDGKYBFWWJA-MNXVOIDGSA-N 0.000 description 1
- MKRDNSWGJWTBKZ-GVXVVHGQSA-N Gln-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MKRDNSWGJWTBKZ-GVXVVHGQSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 description 1
- RDPOETHPAQEGDP-ACZMJKKPSA-N Glu-Asp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RDPOETHPAQEGDP-ACZMJKKPSA-N 0.000 description 1
- XHUCVVHRLNPZSZ-CIUDSAMLSA-N Glu-Gln-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XHUCVVHRLNPZSZ-CIUDSAMLSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- PHONAZGUEGIOEM-GLLZPBPUSA-N Glu-Glu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PHONAZGUEGIOEM-GLLZPBPUSA-N 0.000 description 1
- DVLZZEPUNFEUBW-AVGNSLFASA-N Glu-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N DVLZZEPUNFEUBW-AVGNSLFASA-N 0.000 description 1
- UJMNFCAHLYKWOZ-DCAQKATOSA-N Glu-Lys-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O UJMNFCAHLYKWOZ-DCAQKATOSA-N 0.000 description 1
- GUOWMVFLAJNPDY-CIUDSAMLSA-N Glu-Ser-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O GUOWMVFLAJNPDY-CIUDSAMLSA-N 0.000 description 1
- VNCNWQPIQYAMAK-ACZMJKKPSA-N Glu-Ser-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O VNCNWQPIQYAMAK-ACZMJKKPSA-N 0.000 description 1
- TZXOPHFCAATANZ-QEJZJMRPSA-N Glu-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N TZXOPHFCAATANZ-QEJZJMRPSA-N 0.000 description 1
- HAGKYCXGTRUUFI-RYUDHWBXSA-N Glu-Tyr-Gly Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)O)N)O HAGKYCXGTRUUFI-RYUDHWBXSA-N 0.000 description 1
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 1
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 1
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 1
- TVUWMSBGMVAHSJ-KBPBESRZSA-N Gly-Leu-Phe Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TVUWMSBGMVAHSJ-KBPBESRZSA-N 0.000 description 1
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 1
- HJARVELKOSZUEW-YUMQZZPRSA-N Gly-Pro-Gln Chemical compound [H]NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O HJARVELKOSZUEW-YUMQZZPRSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- MJUUWJJEUOBDGW-IHRRRGAJSA-N His-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 MJUUWJJEUOBDGW-IHRRRGAJSA-N 0.000 description 1
- IAYPZSHNZQHQNO-KKUMJFAQSA-N His-Ser-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N IAYPZSHNZQHQNO-KKUMJFAQSA-N 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101001099460 Homo sapiens Myeloperoxidase Proteins 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- HPCFRQWLTRDGHT-AJNGGQMLSA-N Ile-Leu-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O HPCFRQWLTRDGHT-AJNGGQMLSA-N 0.000 description 1
- SAVXZJYTTQQQDD-QEWYBTABSA-N Ile-Phe-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SAVXZJYTTQQQDD-QEWYBTABSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 1
- PZWBBXHHUSIGKH-OSUNSFLBSA-N Ile-Thr-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PZWBBXHHUSIGKH-OSUNSFLBSA-N 0.000 description 1
- GNXGAVNTVNOCLL-SIUGBPQLSA-N Ile-Tyr-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N GNXGAVNTVNOCLL-SIUGBPQLSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- STAVRDQLZOTNKJ-RHYQMDGZSA-N Leu-Arg-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STAVRDQLZOTNKJ-RHYQMDGZSA-N 0.000 description 1
- VIWUBXKCYJGNCL-SRVKXCTJSA-N Leu-Asn-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 VIWUBXKCYJGNCL-SRVKXCTJSA-N 0.000 description 1
- FIYMBBHGYNQFOP-IUCAKERBSA-N Leu-Gly-Gln Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N FIYMBBHGYNQFOP-IUCAKERBSA-N 0.000 description 1
- OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 1
- VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 1
- YIRIDPUGZKHMHT-ACRUOGEOSA-N Leu-Tyr-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YIRIDPUGZKHMHT-ACRUOGEOSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- BYPMOIFBQPEWOH-CIUDSAMLSA-N Lys-Asn-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N BYPMOIFBQPEWOH-CIUDSAMLSA-N 0.000 description 1
- MRWXLRGAFDOILG-DCAQKATOSA-N Lys-Gln-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MRWXLRGAFDOILG-DCAQKATOSA-N 0.000 description 1
- ZXEUFAVXODIPHC-GUBZILKMSA-N Lys-Glu-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZXEUFAVXODIPHC-GUBZILKMSA-N 0.000 description 1
- LLSUNJYOSCOOEB-GUBZILKMSA-N Lys-Glu-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O LLSUNJYOSCOOEB-GUBZILKMSA-N 0.000 description 1
- UETQMSASAVBGJY-QWRGUYRKSA-N Lys-Gly-His Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 UETQMSASAVBGJY-QWRGUYRKSA-N 0.000 description 1
- QBEPTBMRQALPEV-MNXVOIDGSA-N Lys-Ile-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN QBEPTBMRQALPEV-MNXVOIDGSA-N 0.000 description 1
- RIJCHEVHFWMDKD-SRVKXCTJSA-N Lys-Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RIJCHEVHFWMDKD-SRVKXCTJSA-N 0.000 description 1
- CAODKDAPYGUMLK-FXQIFTODSA-N Met-Asn-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CAODKDAPYGUMLK-FXQIFTODSA-N 0.000 description 1
- OSOLWRWQADPDIQ-DCAQKATOSA-N Met-Asp-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O OSOLWRWQADPDIQ-DCAQKATOSA-N 0.000 description 1
- WPTDJKDGICUFCP-XUXIUFHCSA-N Met-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCSC)N WPTDJKDGICUFCP-XUXIUFHCSA-N 0.000 description 1
- CGUYGMFQZCYJSG-DCAQKATOSA-N Met-Lys-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O CGUYGMFQZCYJSG-DCAQKATOSA-N 0.000 description 1
- LBSWWNKMVPAXOI-GUBZILKMSA-N Met-Val-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O LBSWWNKMVPAXOI-GUBZILKMSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- UNLYPPYNDXHGDG-IHRRRGAJSA-N Phe-Gln-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 UNLYPPYNDXHGDG-IHRRRGAJSA-N 0.000 description 1
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 1
- KZRQONDKKJCAOL-DKIMLUQUSA-N Phe-Leu-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KZRQONDKKJCAOL-DKIMLUQUSA-N 0.000 description 1
- IEIFEYBAYFSRBQ-IHRRRGAJSA-N Phe-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N IEIFEYBAYFSRBQ-IHRRRGAJSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- SMCHPSMKAFIERP-FXQIFTODSA-N Pro-Asn-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]1CCCN1 SMCHPSMKAFIERP-FXQIFTODSA-N 0.000 description 1
- YFNOUBWUIIJQHF-LPEHRKFASA-N Pro-Asp-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O YFNOUBWUIIJQHF-LPEHRKFASA-N 0.000 description 1
- CKXMGSJPDQXBPG-JYJNAYRXSA-N Pro-Cys-Trp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O CKXMGSJPDQXBPG-JYJNAYRXSA-N 0.000 description 1
- LSIWVWRUTKPXDS-DCAQKATOSA-N Pro-Gln-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LSIWVWRUTKPXDS-DCAQKATOSA-N 0.000 description 1
- SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 1
- GRRAECZXRONTEE-UBHSHLNASA-N Ser-Cys-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O GRRAECZXRONTEE-UBHSHLNASA-N 0.000 description 1
- KJMOINFQVCCSDX-XKBZYTNZSA-N Ser-Gln-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KJMOINFQVCCSDX-XKBZYTNZSA-N 0.000 description 1
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 1
- MQQBBLVOUUJKLH-HJPIBITLSA-N Ser-Ile-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MQQBBLVOUUJKLH-HJPIBITLSA-N 0.000 description 1
- OCWWJBZQXGYQCA-DCAQKATOSA-N Ser-Lys-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O OCWWJBZQXGYQCA-DCAQKATOSA-N 0.000 description 1
- KIEIJCFVGZCUAS-MELADBBJSA-N Ser-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N)C(=O)O KIEIJCFVGZCUAS-MELADBBJSA-N 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- XYEXCEPTALHNEV-RCWTZXSCSA-N Thr-Arg-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XYEXCEPTALHNEV-RCWTZXSCSA-N 0.000 description 1
- QGXCWPNQVCYJEL-NUMRIWBASA-N Thr-Asn-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QGXCWPNQVCYJEL-NUMRIWBASA-N 0.000 description 1
- IMULJHHGAUZZFE-MBLNEYKQSA-N Thr-Gly-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IMULJHHGAUZZFE-MBLNEYKQSA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 1
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 1
- QGVBFDIREUUSHX-IFFSRLJSSA-N Thr-Val-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O QGVBFDIREUUSHX-IFFSRLJSSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- WACMTVIJWRNVSO-CWRNSKLLSA-N Trp-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O WACMTVIJWRNVSO-CWRNSKLLSA-N 0.000 description 1
- MDDYTWOFHZFABW-SZMVWBNQSA-N Trp-Gln-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 MDDYTWOFHZFABW-SZMVWBNQSA-N 0.000 description 1
- ADMHZNPMMVKGJW-BPUTZDHNSA-N Trp-Ser-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N ADMHZNPMMVKGJW-BPUTZDHNSA-N 0.000 description 1
- WSMVEHPVOYXPAQ-XIRDDKMYSA-N Trp-Ser-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N WSMVEHPVOYXPAQ-XIRDDKMYSA-N 0.000 description 1
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- YMUQBRQQCPQEQN-CXTHYWKRSA-N Tyr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N YMUQBRQQCPQEQN-CXTHYWKRSA-N 0.000 description 1
- IGXLNVIYDYONFB-UFYCRDLUSA-N Tyr-Phe-Arg Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 IGXLNVIYDYONFB-UFYCRDLUSA-N 0.000 description 1
- NAHUCETZGZZSEX-IHPCNDPISA-N Tyr-Trp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NAHUCETZGZZSEX-IHPCNDPISA-N 0.000 description 1
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 description 1
- QHFQQRKNGCXTHL-AUTRQRHGSA-N Val-Gln-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QHFQQRKNGCXTHL-AUTRQRHGSA-N 0.000 description 1
- VXDSPJJQUQDCKH-UKJIMTQDSA-N Val-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N VXDSPJJQUQDCKH-UKJIMTQDSA-N 0.000 description 1
- PHZGFLFMGLXCFG-FHWLQOOXSA-N Val-Lys-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N PHZGFLFMGLXCFG-FHWLQOOXSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 101150089730 gly-10 gene Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 102000051251 human MPO Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000001096 hypoplastic effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- QKWLAUAUUGXSSE-UHFFFAOYSA-L prohexadione-calcium Chemical compound [Ca+2].CCC(=O)C1=C([O-])CC(C([O-])=O)CC1=O QKWLAUAUUGXSSE-UHFFFAOYSA-L 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 108010072415 tumor necrosis factor precursor Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
A novel member of the tumor necrosis factor (TNF) family was identified and observed to be involved in inflammation and necrosis, especially of the liver, myelopoiesis and bone resorption. The polypeptide is termed AGP-1. Nucleic acid sequences, vectors and host cells for the expression of AGP-1 are disclosed. Methods for identifying antagonists of AGP-1, pharmaceutical compositions comprising AGP-1 and methods of treatment using AGP-1 and AGP-1 antagonists are also disclosed.
Description
CA 022~6464 1998-11-27 W O 97/46686 PCT~US97/09895 TUMOR NECROSIS FACTOR-RELATED POLYPEPTIDE
Fiel~ of the Invention The invention relates to AGP-1, a tumor necrosis factor-related polypeptide involved in inflammation, myelopoiesis and bone resorption. Nucleic acid sequences, vectors and host cells for the expression of AGP-1 are disclosed. Also encompassed are pharmaceutical compositions comprising AGP-l, methods of identifying antagonists of AGP-l and methods of treatment using AGP-1 or AGP-1 antagonists.
Background of the Invention The tumor necrosis factor family is a growing group of cytokines which function as mediators of immune regulation, acute and chronic inflammatory responses, and programmed cell death. Tumor necrosis factor (TNFa) is the prototypical member of this family which also includes lymphotoxin (LTa/ TNF~), lymphotoxin ~ (LT~), and ligands for CD27, CD30, CD40, OX40, 4-lBB, and Fas.
Homology among these family members is confined to the carboxy-terminal 150 amino acid residues, with the highest degree of homology within the ~-strand regions involved in subunit contacts which lead to oligomerization. With the exception of LTa, which is a secreted protein, all the ligands in this family are type II membrane proteins. The homologous carboxy-terminal domains are extracellular, and the shorter non-homologous amino-terminal regions are intracellular. The membrane bound form of TNFa can be the target of proteolytic cleavage, generating a soluble form of TNFa which circulates in certain disease states.
CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 As systemic delivery of TNFa induces toxic shock and widespread tissue necrosis, TNFa may contribute to the morbidity and mortality associated with a variety of infectious diseases, including septic shock, autoimmune disorders and graft-versus-host disease.
The TNF family of cytokines exert their biological effects through their interactions with a family of receptors which are generally characterized as Type I membrane proteins with cysteine-rich pseudorepeats in their extracellular domains. Of the twelve TNF receptor superfamily members identified to date, only the two poxvirus genes, T2 and A53R, encode soluble, secreted receptors. Whereas soluble forms of TNFa play an important role in the immune response, the interaction of membrane bound ligands and receptors of this family, particularly on T and B cells, likely plays a major role in cell-cell cross-talk within the immune system. In this regard, signaling through FasL and its receptor is believed to play an important role in T-cell mediated cytotoxicity.
Perhaps the most intriguing activity associated with this family is their ability to induce programmed cell death through the apoptotic pathway, a phenomena which is crucial in many areas of vertebrae development, including T-cell development. Of the known TNF family members, TNFa, LTa and FasL have all been demonstrated to induce apoptosis of certain cells under the correct conditions. Although the apoptotic effects of TNFa and LTa appear to be limited to a minimal number of cell types, signalling through Fas has been demonstrated to induce apoptosis of numerous transformed cell lines and chronically activated T cell clones.
Additionally, two mutations that accelerate autoimmune disease (lpr and gld), resulting in lymphadenopathy and splenomegaly in mutant mice, are known to correspond to CA 022~6464 1998-11-27 W O 97146686 PCT~US97/09895 mutations within the genes encoding Fas and FasL, respectively.
In view of the involvement of TNF and TNF-related family members in conditions associated with inflammation, infectious disease, immune system disorders and apoptotic cell death, it is desirable to identify additional related TNF family members.
It is an object of this invention to identify TNF-related molecules for the purpose of developing treatments for disorders related to TNF and TNF-related molecules.
A novel gene has been identified which encodes a polypeptide having significant homology to the TNF
family member FasL. The polypeptide has been termed AGP-1. Transgenic mice expressing murine AGP-1 in the liver exhibit hepatic inflammation and necrosis, bile duct hyperplasia, as well as pathological findings supportive of direct or indirect systemic effects of the factor. The nucleotide and amino acid sequence of AGP-1 was found to be identical to the sequence reported for TNF-related apoptosis-inducing ligand (TRAIL, see Wiley et al. Immunity 3, 673-682 (1995)). TRAIL was observed to induce apoptosis in a wide variety of transformed cell lines.
Summary of the Invention A novel member of the tumor necrosis factor family, termed AGP-1, has been identified from a murine cDNA library and expressed in a transgenic mouse system.
AGP-l is involved in myelopoiesis accompanied by an increase in neutrophils and lymphocytes, inflammation and necrosis of the liver, and bone resorption. Human AGP-1 has also been identified.
The invention provides for nucleic acids encoding a polypeptide having at least one of the CA 022~6464 1998-11-27 W 097/46686 PCTrUS97/09895 biological activities of AGP-1, vectors and host cells expressing the polypeptide, and method for producing recombinant AGP-1. Antibodies or fragments thereof which specifically bind AGP-1 are also provided.
Methods of identifying antagonists of AGP-l which reduce or eliminate at least one of the biological activities of AGP-1 are also encompassed by the invention. Such antagonists include peptides, proteins, carbohydrates or small molecular weight organic molecules which bind to AGP-l or to its receptor(s) and interfere with AGP-1 receptor activation.
AGP-1 may be used to treat hematopoeitic disorders characterized by a decrease in cell population of the bone marrow. AGP-1 antagonists may be used to treat inflammatory conditions. AGP-1 antagonists may also be used to treat bone disorders resulting from an increase in bone resorption. Pharmaceutical compositions comprising AGP-1 and AGP-l antagonists are also encompassed by the invention.
Description of the Figures ~ igure 1. cDNA and amino acid sequence of murine AGP-1.
Figure 2. cDNA and amino acid sequence of human AGP-1.
Figure 3. Hematoxylin and Eosin (H&E) stained sections of liver from non-transgenic mouse #12 (A) and HEAGP F1 transgenic mouse #75-13 (B). B illustrates marked proliferative cholangiohepatitis characterized by periportal bile duct hyperplasia and inflammation (arrowheads in B; arrowhead in A points to a normal portal tract for contrast) with scattered foci of hepatocellular necrosis (asterisk in A). Bars = 50 ~m.
CA 022~6464 l998-ll-27 W 097/46686 PCTrUS97/09895 Figure 4. Myeloperoxidase stained sections of HEAGP F1 transgenic (B - mouse #75-13) and non-transgenic (A mouse #12) spleen. B illustrates splenomegaly in the transgenic mouse primarily caused by an expanded red pulp (asterisks) due to increased red pulp myelopoiesis (arrowheads in B illustrate aggregates of myeloperoxidase positive myeloid precursors) in the transgenic spleen as well as by white pulp lymphoid hyperplasia (arrows in B vs. A). Bars = 250 ~m.
Figure 5. TRAP stained sections of bone marrow from a non-transgenic control mouse (A - mouse #12) and an HEAGP F1 transgenic mouse (mouse #75-13) illustrating an apparent increase in the number of TRAP+ osteoclasts (arrows) lining bony trabeculae in the transgenic bone marrow (B) vs. the non-transgenic marrow (A). Bars =
25 ~m.
Detailed Description of the Invention The invention provides for a novel member of the TNF receptor superfamily, termed AGP-1. AGP-1 refers to a polypeptide having an amino acid sequence of mammalian AGP-1 or a derivative thereof and having at least one of the biological activities of AGP-l. In preferred embodiments, AGP-1 is mouse or human AGP-l.
cDNA and amino acid sequences of mouse and human AGP-1 are shown in Figures 1 and 2, respectively. The biological activities of AGP-1 include, but are not limited to, involvement in myelopoiesis, inflammation and necrosis, especially in the liver, and bone resorption.
The invention provides for isolated nucleic acids encoding polypeptides having one or more of the biological properties of AGP-l. As used herein, the CA 022~6464 1998-11-27 term nucleic acid represents cDNA, genomic DNA, wholly or partially synthetic DNA or RNA. The nucleic acids of the invention are selected from the group consisting of:
a) the nucleic acids as shown in Figure 1 (SEQ ID NO: 1) or Figure 2 (SEQ ID NO: 3);
b) nucleic acids which hybridize to the polypeptide coding regions of the nucleic acids shown in Figure 1 (SEQ ID NO: 1) or Figure 2 (SEQ ID NO: 3) and remain hybridized to the nucleic acids under high stringency conditions; and c) nucleic acids which are degenerate to the nucleic acids of (a) or (b).
Nucleic acid hybridizations typically involve a multi-step process comprising a first hybridization step to form nucleic acid duplexes from single strands followed by a second hybridization step carried out under more stringent conditions to selectively retain nucleic acid duplexes having a degree of homology which depends upon the stringency of hybridization during the second step. The conditions of the first hybridization step are generally not crucial, provided they are not of higher stringency than the second hybridization step.
Generally, the second hybridization is carried out under conditions of high stringency, wherein "high stringency"
conditions refers to conditions of temperature and salt which are about 12-20~C below the melting temperature (Tm) of a perfect hybrid of part or all of the complementary strands corresponding to SEQ. ID. NO: 1 or, alternatively, are about 12-20~C below the Tm Of a perfect hybrid of part or all of the complementary strands corresponding to SEQ. ID. NO: 3. In one embodiment, "high stringency" conditions refer to conditions of about 65~C and not more than about lM Nat.
It is understood that salt concentration, temperature and/or length of incubation may be varied in either the first or second hybridization steps such that one CA 022~6464 1998-11-27 W O 97/46686 PCTrUS97/09895 obtains the hybridizing nucleic acid molecules according to the invention. Conditions for hybridization of nucleic acids and calculations of Tm for nucleic acid hybrids are described in Sambrook et al. Molecular Cloninq: A Tl~horatory Manu~l Cold Spring Harbor Laboratory Press, New York. (1989).
The nucleic acids of the invention may hybridize to part or all of the polypeptide coding regions of AGP-l as shown in SEQ ID NO: 1 and SEQ ID NO:
3, and therefore may be truncations or extensions of the nucleic acids in SEQ ID NO: 1 and SEQ ID NO: 3.
Truncated or extended nucleic acids are encompassed by the invention provided that they retain one or more of the biological properties of AGP-1, such as stimulating myelopoiesis, bone resorption or an inflammatory response. In one embodiment, the nucleic acid will encode a polypeptide of at least about 10 amino acids.
In another embodiment, the nucleic acid will encode a polypeptide of at least about 20 amino acids. In yet another embodiment, the nucleic acid will encode polypeptides of at least about 50 amino acids. The hybridizing nucleic acids may also include noncoding sequences located 5' and/or 3' to the AGP-1 coding regions. Noncoding sequences include regulatory regions involved in AGP-1 expression, such as promoters, enhancer regions, translational initiation sites, transcription termination sites and the like.
In preferred embodiments, the nucleic acids of the invention encode mouse AGP-1 or human AGP-1. Mouse AGP-1 is shown in Figure 1 and SEQ. ID. NO: 2 and human AGP-1 is shown in Figure 2 and SEQ. ID. NO: 4. Nucleic acids may encode a full-length form of AGP-1 which is a membrane-bound or soluble forms of AGP-1 lacking part or all of the transmembrane region. The predicted transmembrane region for human AGP-1 includes residues 16-36 as shown in S~Q. ID. NO: 4. Deletions of part or CA 022~6464 1998-11-27 all these residues would be expected to produce soluble forms of AGP-1.
The nucleic acids of the invention will be linked with DNA sequences so as to express biologically active AGP-l. Sequences required for expression are known to those skilled in the art and include promoters and enhancer sequences for initiation of RNA synthesis, transcription termination sites, ribosome binding sites for the initiation of protein synthesis, and leader sequences for secretion. Sequences directing expression and secretion of AGP-1 may be homologous, i.e., those sequences in the genome involved in AGP-1 expression and secretion, or may be heterologous. A variety of plasmid vectors are available for expressing AGP-1 in host cells. One example is plasmid pDSR~ described in PCT Application No. 90/14363 which may be used for expression in mammalian hosts. AGP-l coding regions may also be modified by substitution of preferred codons for optimal expression in a given host. Codon usage in bacterial, plant, insect and mammalian host systems is known and may be exploited by one skilled in the art to optimize mRNA translation. In addition, vectors are available for the tissue-specific expression of AGP-1 in transgenic animals. Retroviral and adenovirus-based gene transfer vectors may also be used for the expression of AGP-l in human cells for in vivo therapy (see PCT Application No. 86/00922).
Procaryotic and eucaryotic host cells expressing AGP-1 are also provided by the invention.
Host cells include bacterial, yeast, pl-ant, insect or mammalian cells. AGP-1 may also be produced in transgenic animals such as mice or goats. Plasmids and vectors containing the nucleic acids of the invention are introduced into appropriate host cells using transfection or transformation techniques known to one skilled in the art. Host cells may contain DNA
CA 022~6464 1998-11-27 W O 97/46686 PCTrUS97/09895 g _ sequences encoding the full-length AGP-l gene as shown in Figure 1. Host cells will also process AGP-1 encoded by the full-length gene to the mature form or produce the mature form without processing by expression of DNA
sequences encoding same. Examples of mammalian host cells for AGP-1 expression include, but are not limited to COS, CHOd-, 293 and 3T3 cells.
The invention also provides AGP-1 as the product of procaryotic or eucaryotic expression of an exogenous DNA sequence, i.e., AGP-1 is recombinant AGP-1. Exogenous DNA sequences include cDNA, genomic DNA and synthetic DNA sequences. AGP-1 may be the product of bacterial, yeast, plant, insect or mammalian cells expression. AGP-1 produced in bacterial cells will have an N-terminal methionine residue. The invention also provides for a process of producing AGP-1 comprising growing procaryotic or eucaryotic host cells transformed or transfected with nucleic acids encoding AGP-1 and isolating polypeptide expression products of the nucleic acids.
Polypeptides which are mamalian AGP-1 or are derivatives thereof are encompassed by the invention. A
derivative of AGP-1 refers to a polypeptide having an addition, deletion, insertion or substitution of one or more amino ac~ds such that the resulting polypeptide has at least one of the biological activities of AGP-l. The derivative may be naturally occurring, such as a polypeptide product of an allelic variant or a mRNA
splice variant:, or it may be constructed using techniques available to one skilled in the art for manipulating and synthesizing nucleic acids.
AGP-1 polypeptides may be full-length polypeptides or fragments thereof which, in preferred embodiments, are at least about ten amino acids, at _ CA 022~6464 1998-11-27 W O 97146686 PCTrUS97/09895 least about 20 amino acids, or at least about 50 amino acids in length. AGP-1 full-length polypeptides and fragments preferably have the amino acid sequence in Figure 1 or 2 or a portion thereof. The polypeptides may or may not have an amino terminal methionine residue.
Also included in the invention are AGP-1 polypeptides which have undergone post-translational modifications (e.g., addition of N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition of an N-terminal methionine residue as a result of procaryotic host cell expression. As mouse and human AGP-1 are encoded as transmembrane proteins, soluble forms of AGP-1 are also envisioned. Such soluble forms may be readily constructed by removal of the transmembrane region of the polypeptide. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.
AGP-1 chimeric proteins comprising part or all of an AGP-1 amino acid sequence fused to a heterologous amino acid sequence are also included. The heterologous sequence may be any sequence which allows the resulting fusion protein to retain the activity of AGP-1. The heterologous sequences include, for example, immunoglobulin fusions, such as an Fc region of IgG, which provide dimerization, or fusions to enzymes which provide a label for the polypeptide.
The polypeptides of the invention are isolated and purified from tissues and cell lines which express AGP-1 and from transformed host cells expressing AGP-1, or purified from cell cultures containing the secreted protein. Isolated AGP-1 polypeptide is free from CA 022~6464 1998-11-27 W O 97/46686 PCT~US97/09895 association with human proteins and other cell constituents.
Also provided by the invention are chemically modified derivatives of AGP-1 which provide additional advantages such as increased stability, longer circulating time, or decreased immunogenicity (see for example U.S. Patent No. 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.
A method for the purification of AGP-1 from natural sources (e.g. tissues and cell lines which normally express AGP-1) and from transfected host cells is also encompassed by the invention. The purification process may employ one or more standard protein purification steps in an appropriate order to obtain purified protein. The chromatography steps can include ion exchange, gel filtration, hydrophobic interaction, reverse phase, chromatofocusing, affinity chromatography employing an anti-AGP-1 antibody or biotin-streptavidin affinity complex and the like.
The invention also encompasses AGP-1 antagonists and the methods for obtaining them. An antagonist will reduce or eliminate one or more of the biological activities of AGP-1. As examples, an AGP-1 antagonist may act as an anti-inflammatory agent, or may act to inhibit bone-resorption. AGP-1 antagonists include substances which bind to AGP-1 or to AGP-1 receptors in a manner to prevent normal ligand-receptor interaction and substances which regulate the expression CA 022~6464 1998-11-27 W 097/46686 PCT~US97109895 - 12 -of AGP-1. Substances which bind to AGP-1 or to AGP-1 receptors include proteins, peptides, carbohydrates and small molecular weight organic compounds. Examples of protein inhibitors include anti-AGP-l antibodies, anti-AGP-1 receptor antibodies and soluble forms of AGP-1 receptor comprising part or all of the extraceullular domain of the AGP-1 receptor. Substances which regulate AGP-1 expression typically include nucleic acids which are complementary to nucleic acids encoding AGP-1 or AGP-1 receptors and which act as anti-sense regulators of expression.
Methods for indentifying compounds which interact with AGP-l are also encompassed by the invention. The method comprises incubating AGP-1 with a compound under conditions which permit binding of the compound to AGP-1 and measuring the extent of binding.
The compound may be substantially purlfied or present in a crude mixture. Binding compounds may be proteins, peptides, carbohydrates or small molecular weight organic compounds. The compounds may be further characterized by their ability to enhance or reduce AGP-1 biological activity and therefore act as AGP-l agonists or as AGP-1 antagonists. Preferably, the method is used to identify AGP-1 antagonists.
Antibodies specifically binding the AGP-1 polypeptides of the invention are also encompassed by the invention. The antibodies may be produced by immunization with full-length membrane-bound AGP-1, soluble AGP-1, or a peptide fragment thereof, and the antibodies may be polyclonal or monoclonal. In addition, the antibodies of the invention may be recombinant, such as chimeric antibodies wherein the murine constant regions on light and heavy chains are replaced by human sequences, or CDR-grafted antibodies wherein only the complementary determining regions are CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 of murine origin. Antibodies of the invention may also be human antibodies prepared, for example, by immunizatlon of transgenic animals capable of producing human antibodies (see, for example, PCT Application No. WO93/12227). The antibodies are useful for detecting AGP-1 in biological samples, thereby allowing the identification of cells or tissues which produce AGP-1. In addition, antibodies which bind to AGP-1 and prevent receptor interaction may also be useful for blocking the effects of AGP-1.
The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of the AGP-1 polypeptide of the invention together with a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and/or adjuvant. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an AGP-1 antagonist. The term "therapeutically effective amount" means an amount which provides a therapeutic effect for a specified condition and route of administration. The composition may be in a liquid or lyophilized form and comprises a diluent (Tris, acetate or phosphate buffers) having various pH
values and ionic strengths, solubilizer such as Tween or Polysorbate, carriers such as human serum albumin or gelatin, preservatives such as thimerosal or benzyl alcohol, and antioxidants such as ascrobic acid or sodium metabisulfite. Also encompassed are compositions comprising AGP-1 modified with water soluble polymers to increase solubility, stability, plasma half-life and bioavailability. Compositions may also comprise incorporation of AGP-1 into liposomes, microemulsions, micelles or vesicles for controlled delivery over an extended period of time. Selection of a particular composition will depend upon a number of factors, _ .
CA 022~6464 l998-ll-27 W 097/46686 PCT~US97/09895 including the condition being treated, the route of administration and the pharmacokinetic parameters desired. A more extensive survey of component suitable for pharmaceutical compositions is found in Remington's Pharmaceutical Sciences, 18th ed. A.R. Gennaro, ed.
Mack, Easton, PA (1980).
Compositions of the invention may be administered by injection, either subcutaneous, intravenous or intramuscular, or by oral, nasal, pulmonary or rectal administration. The route of administration eventually chosen will depend upon a number of factors and may be ascertained by one skilled in the art.
The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of the nucleic acids of the invention together with a pharmaceutically acceptable adjuvant. Nucleic acid compositions will be suitable for the delivery of part or all of the APG-l coding region and/or flanking regions to cells and tissues as part of an anti-sense therapy regimen.
Hepatic expression of AGP-l in transgenic mice resulted in marked myelopoiesis accompanied by an increase in neutrophils and lymphocytes. Therefore, AGP-l may be used to treat hematopoietic disorders that are associated with a decrease in the population of cells in bone marrow. In particular, AGP-l may be used to treat conditions resulting in low white blood cell levels, particularly reduced levels of neutrophils and lymphocytes. Such conditions may result from disease, injury or exposure to certain environmental agents known to suppress bone marrow levels. It is understood that AGP-l may be administered alone or in combination with other factors to treat hematopoietic disorders. In one embodiment, AGP-l is used in conjunction with a CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 therapeutically effective amount of a factor which stimulates hematopoiesis. Such factors include erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF), megakaryocyte growth and differentiation factor (MGDF), granulocyte-macrophage stimulating factor (GM-CSF), stem cell factor (SCF), interleukin-3 (IL-3) and interleukin-6 (IL-6).
Hepatic expression of AGP-l in transgenic mice resulted in increased inflammation and necrosis, especially in the liver. This effect may be the result of a high local concentration of AGP-l occurring in the liver during transgene expression. Thus, antagonists of AGP-l may be used as anti-inflammatory agents which are administered to patients susceptible to or suffering from an inflammatory condition. Inflammatory conditions include rhematoid arthritis, systemic lupus erythematosis, psoriasis, systemic and localized amyloidosis, Sjogerns syndrome, sclerodoma, dermatomyositls, glomerulonephritis, and inflammation arising from infections and parasitic diseass. AGP-l antagonists which reduce or eliminate inflammation may be administered alone or in combination with a therapeutically effective amount of an anti-inflammtory agent such as a corticosteroid, a non-steroidal anti-inflammatory agent (NSAID), or cyclosporin A.
AGP-l antagonists may also reduce or eliminate necrosis associated with an inflammatory condition.
AGP-l is also involved in stimulation of osteoclasts which promote bone resorption through mineralization of the bone matrix. Increase in bone resorption rates that exceed rates of bone formation can lead to various bone disorders including osteoporosis, osteomyelitis, hypercalcemia, osteopenia brought on by surgery or steroid administration, Paget's disease, osteonecrosis, bone loss due to rheumatoid arthritis, periodontal bone loss, and osteolytic metastasis.
CA 022~6464 l998-ll-27 W O 97146686 PCTrUS97/09895 Antagonists of AGP-1 may be administered to patients suffering from disorders brought on by increased osteoclast activity and increased bone resorption.
AGP-1 antagonists may be administered alone or in c~mbination with a therapeutically effective amount a bone growth promoting agent including bone morphogenic factors designated BMP-1 to BMP-12, transforming growth factor-~ and TGF-~ family members, interleukin-1 inhibitors, TNF~ inhibitors, parathyroid hormone, E series prostaglandins, bisphosphonates and bone-enhancing minerals such as fluoride and calcium.
The following examples are offered to more fully illustrate the invention, but are not construed as limiting the scope thereof.
Identification and Isolation of Murine and Human AGP-1 Genes A. Murine AGP-1 Materials and method for cDNA cloning and analysis are described in Sambrook et.al. Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989). A cDNA library was constructed using mRNA isolated from 5, 6, and 7 day post-5FU
treated bone marrow from C57/B6 female mice. Mice were treated with 150mg/kg 5-fluorouracil (5FU), intraperitoneally, on each of three consecutive days.
On day 5, 6, and 7 post-5FU treatment both femurs and tibias were harvested, and plugs flushed with PBS.
Bones were crushed with mortar and pestle and combined with the bone marrow plugs. The poly A+ mRNA was purified using Fast Track mRNA Kit (InVitrogen, San Diego, CA) using the manufacturer's recommended CA 022~6464 1998-11-27 W097/46686 PCT~S97/09895 procedures. A random primed cDNA library was prepared using the Superscript Plasmid System (Gibco BRL, Gaithersburg, MD). A random cDNA primer containing an internal Not I restriction site was used to initiate first strand synthesis and had the following double strand sequence:
5'-CCTCTGCGGCCGCTACANNNNNNNNT-3' (SEQ lD NO: 5) 3'-pGGAGACGCCG~CGA-5' (SEQ ID NO: 6) The first strand cDNA synthesis reaction was assembled using l~g of the mRNA and 150 ng of the Not 1 random primer. After second strand synthesis, the reaction products were extracted with the phenol:chloroform:isoamyl alcohol mixture and ethanol precipitated. The double strand (ds) cDNA products were ligated to the following ds oligonucleotide adapter (Gibco BRL):
5'-TCGACCCACGCGTCCG-3' (SEQ ID NO: 7) 3'-GGGTGCGCAGGCp-5' (SEQ ID NO: 8~
After ligation the cDNA was digested to completion with Not 1, extracted with phenol:chloroform:isoamyl alcohol (25:24:1 ratio) and ethanol precipitated. The resuspended cDNA was then size fractionated by gel filtration using the premade columns provided with the Superscript Plasmid System (Gibco BRL) as recommended by the manufacturer. The fractions containing the largest cDNA products were ethanol precipitated and then directionally ligated into Not 1 and Sal 1 digested pMOB vector DNA (Strathmann et.
al. Science 252, 802-808 (1991)). The ligated cDNA was introduced into electrocompetent XL1-Blue E. coli (Stratagene, I,aJolla, CA) by electroporation.
Approximately 20,000 colonies were picked and arrayed into 96 well microtiter plates containing 200 ~l of CA 022~6464 1998-11-27 W O 97/46686 PCT~US97/09895 L-broth, 7.5% glycerol, 50 ~g/ml ampicillin and 12.5~g/ml tetracycline. The cultures were grown overnight at 37 C, a duplicate set of microtiter plates were made using a sterile 96 pin replicating tool, then both sets were stored at -80 C for further analysis.
To sequence random murine 5FU-treated bone marrow cDNA clones, sequencing template was prepared by PCR amplification of cloned cDNA inserts using vector primers. Glycerol stocks of cDNA clones were thawed, and small aliquots were diluted 1:25 in distilled water.
Approximately 3.0 ~l of diluted bacterial cultures were added to PCR reaction mixture (Boehringer-Mannheim) containing the following oligonucleotides:
5' TGTAAAACGACGGCCAGT 3' (SEQ ID NO: 9) 5' CAGGAAACAGCTATGACC 3' (SEQ ID NO: 10) The reactions were incubated in a thermocycler (Perkin-Elmer 9600) with the following cycle conditions:
94 C for 2 minutes; 94 C for 5 seconds, 50 C for 5 seconds and 72 C for 3 minutes for 30 cycles and then a final extension at 72 C for 4 mlnutes. After incubation in the thermocycler, the reactions were diluted with 2.0 ml of water. The amplified DNA
fagments were further purified using Centricon columns (Princeton Separations) using the manufacturer's recommended procedures. In some instances, low primer and deoxynucleoside triphosphate concentrations were used in the amplification reactions, and in those instances, Centricon purification was not necessary.
The PCR reaction products were sequenced on an Applied Biosystems 373A automated DNA sequencer using T3 primer:
5'-CAATTAACCCTCACTAAAGG-3' (SEQ ID NO: 11) CA 022~6464 1998-11-27 W O 97/46686 PCTrUS97/09895 Taq dye-terminator reactions (Applied Biosystems) following the manufacturer's recommended procedures.
The resulting 5' nucleotide sequence obtained from randomly picked cDNA clones were translated and then compared to the existing database of known protein sequences using a modified version of the FASTA program (Pearson, et. al. Meth. Enzymol. 183, 63-98 (199~)).
Translated sequences were also analyzed for the presence of specific tumor necrosis factor superfamily motifs, using the sequence profile method of Gribskov, et. al.
(Proc. Natl. Acad. Sci. USA 83, 4355-4359 (1987)) as modified by Ll~ethy et al. (Protein Science 3, 139-146 (1994)).
Using the FASTA and Profile search data, an EST designated muAGP-EST1 was identified as a possible new member of the TNF family. The muAGP-EST1 clone contained an 86~ bp insert with an open reading frame of about 90 amino acids which was found to have significant homology to pig lymphotoxin-~ precursor (TNF-~) and rabbit tumor necrosis factor precursor (TNF-~) (cachectin). The region compared showed an overlap of 63 amino acids and a 27% homology to TNF-~ and a 71 amino acid overlap and 30% homology to TNF-~.
Profile analysis using the TNF family profile yielded a z score of 13.5, indicating that the muAGP-EST1 clone was encoding a possible new member of the TNF family.
To obtain a full-length clone, an internal EST
database was searched for overlapping clones and two other murine EST clones were identified. One EST clone designated muAGP-EST2 from a murine irradiated small intestine library gave a sequence which overlapped the sequence obtained from the muAGP-EST1 clone. The muAGP-EST2 clone was subsequently sequenced in its entirety. The insert was 3098 bp and contained an open reading frame of 291 amino acids which was deduced to be the full-length AGP-1 sequence. The nucleotide sequence CA 022~6464 1998-11-27 W O 97t46686 PCTrUS97/098g5 and deduced amino acid of murine AGP-1 is shown in Figure 1.
B. Human AGP-1 A cDNA library was constructed using RNA from human bladder carcinoma cell line 5637 which had been stimulated with 2OnM of PMA for about nine hours. For this library, mRNA was isolated from a membrane bound polysomal fraction of RNA (Mechler Methods in Enzymology 152, 241-248 (1987)). The poly A~ mRNA
fraction was isolated from the total RNA preparation by using the Fast Track mRNA Isolation Kit (InVitrogen) according to the manufacturer's recommended procedure.
A directional random primed cDNA library was prepared essentially as described for the 5-FU mouse bone marrow library above. The cDNA inserts were sequenced as described above for the mouse cDNA clones.
The resulting 5' nucleotide sequences obtained from randomly picked cDNA clones were translated and compared to the existing database of known protein sequences using a modified version of the FASTA program (Pearson et al. ibid). Translated sequences were also analysed for the presence of specific motifs found in the tumor necrosis factor superfamily using the sequence profile method of Gribskov et.al. ibid as modified by Luethy et.al. ibid.
Using the FASTA and Profile search data, an EST from the 5637 cell line cDNA library designated huAGP-EST1 was identified as a possible new member of the TNF family. huAGP-EST1 contained an 446 bp insert with an open reading frame of about 84 amino acids.
Translation of the huAGP-EST1 nucleotide sequence gave an amino acid sequence which was 77% identical to the deduced amino acid sequence of murine AGP-1 when compared using FASTA analysis. This high degree of CA 022~6464 1998-11-27 sequence similarity identifies huAGP-EST1 as the human homolog of murine AGP-1.
To obtain a full-length clone, an internal EST
database was searched for overlapping clones and one other murine EST clone was identified. This clone, designated huAGP-EST2, was from a human peripheral blood megakaryocyte cDNA library and had an insert of 1~28 bp which overlapped the huAGP-EST1 clone. The overlapping clones had an open reading frame of 281 amino acids.
The full-length human AGP-1 was obtained as a composite of the sequences from the huAGP-EST1 and huAGP-EST2 clones. The nucleotide sequence and deduced amino acid sequence of human AGP-1 is shown in Figure 2.
Expression of AGP-1 in transgenic mice A. PCR and subcloning The TNF~-related clone muAGP-EST2 was used as template to PCR amplify the coding region for subcloning into an APOE-liver specific expression vector (Simonet et al. J. Clin. Invest. 94, 1310-1319 (1994), and PCT
Application No. WO94/11675). The oligonucleotides used for amplification were:
5'-GAC TAG TCA GAC CTG GAC AGC AGT ATG CCT TC-3' (SEQ ID NO: 12); and 5'-ATA AGA ATG CGG CCG CTA AAC TAT GGG TAC TTT AGG
GCT GTG TTT G-3' (SEQ ID NO: 13) The conditions for PCR were: 94~C for 1 minute, followed by 25 cycles of 94 C for 20 sec, 63 C
for 30 sec, and 74 C for 1 minute. The PCR reactions contained 1 x PFU buffer, 50 uM dNTPs, 20 pmol of each CA 022~6464 l998-ll-27 W O 97/46686 PCT~US97/Og895 oligo, 10 ng of DNA template and 2.5 units of PFU enzyme in a total volume of 50 ul. Following amplification, the samples were purified over Qiagen PCR columns and digested overnight with SpeI and NotI restriction enzymes. The digested products were extracted and precipitated and subcloned into the ApoE promoter expression vector.
Ligations were transformed into E. coli strain DH5a and colonies were minipreped for analysis of the insert. Two clones containing the desired size insert were grown in 100ml TB cultures and plasmid DNA was prepared. The two clones were sent to sequencing to verify the authenticity of the insert. One was selected for microinjection to generate transgenic mice. This transgene was designated HE-AGP.
B. Preparation of transgenic mice For microinjection, the HE-AGP plasmid was purified through two rounds of CsCl. The plasmid was digested with XhoI and Ase I, and the 3.9 kb transgene insert was purified on a 0.8% BRL ultrapure DNA agarose gel by electrophoresis onto NA 45 paper. The purified fragment was diluted to 1 ug/ml in 5 mM Tris, pH 7.4, 0.2 mM EDTA. Single-cell embryos from BDF1 x BDF1-bred mice were injected essentially as described (Brinster et al., 1985), except that injection needles were beveled and siliconized before use. Embryos were cultured overnight in a CO2 incubator and 15 to 20 two-cell embryos were transferred to the oviducts of pseudopregnant CD1 female mice.
C. Screening of transgenic founders Following term pregnancy, 105 offspring were obtained from implantation of microinjected embryos. Of the 105 offspring, 17 were identified as transgenic founders by screening for the HE-AGP transgene in DNA
CA 022~6464 1998-11-27 W O 97/46686 PCT~US97/09895 prepared from ear and tall biopsies. The PCR screening involved amplification of a 369 bp region of the human Apo E intron which was included in the expression vector. The oligos used for PCR amplification were:
5'-GCC TCT AGA AAG AGC TGG GAC-3' (SEQ. ID. NO: 14) 5'-CGC CGT GTT CCA TTT ATG AGC-3' (SEQ. ID. NO: 15 The conditions for PCR were: 94 C for 2 minute, followed by 30 cycles of 99 C for 1 min, 63 C
for 20 sec, and 72 C for 30 sec. The PCR reactions contained 1 x Taq buffer, 100 uM each dNTPs, 20 pmol of each oligo, 1 ul of DNA template extract and 0.5 units of taq enzyme in a total volume of 50 ul.
D. Preparation and analysis of total RNA for Northern analysis At 8-10 weeks of age, 8 of the 17 transgenics (#'s 10, 27, 52, 53, 69, 72, 76 and 77~ and 4 control littermates (#'s 55, 56, 57, and 58) were sacrificed for necropsy and pathological analysis (See Example 3).
Liver was isolated from the remaining 9 founders (#'s 25, 42, 44, 45, 48, 50, 67, 74, and 75) by partial hepatectomy. For partial hepatectomy, the mice were anesthetized with avertin and a lobe of liver was surgically removed. Total cellular RNA was isolated from livers of all transgenic founders, and 5 negative control littermates as described (McDonald et al.
(1987~). Northern blot analysis was performed on these samples to assess the level of transgene expression.
Approximately 10ug of total RNA from each animal liver was resolved by electrophoresis denaturing gels (Ogden et al. (1987)), then transferred to HYBOND-N nylon membrane (Amersham), and probed with 32p dCTP-labelled pB1.1 insert DNA. Hybridization was performed overnight at 42 C in 50% Formamide, 5 x SSPE, 0.5% SDS, 5 x CA 022~6464 l998-ll-27 W 097/46686 PCT~US97/09895 Denhardt's solution, 100 ug/ml denatured salmon sperm DNA and 2-4 x 106 cpm of labeled probe/ml of hybridization buffer. Following hybridization, blots were washed twice in 2 x SSC, 0.1% SDS at room temperature for 5 min each, and then twice in 0.1 x SSC, 0.1% SDS at 55 C for 5-10 min each. Expression of the transgene in founder and control littermates was determined following autoradiography.
The Northern blot data indicate that 13 of the transgenic founders express detectable levels of the transgene mRNA (animal #'s 10, 42, 44, 45, 4~, 50, 52, 53, 67, 69, 74, 75 and 76). The negative control mice expressed no transgene-related mRNA. The highest expressing founders From the group that were necropsied 15 were #'s 52, 69 and 76. The highest expressing animals from the remaining group of founder's were #'s 42, 45, 67, and 75. Six of the founder's that were analyzed by hepatectomy were subsequently bred to generate F1 offspring for further analysis.
Pathology Analysis of Transgenic Mice Expressing AGP-1 A. Necropsy Mice from two separate studies were examined.
In the first study, five BDF1 female mice which were founder transgenics for the murine AGP-1 molecule targeted to the liver via an apolipoprotein E promoter as well as four male non-transgenic littermate mice were necropsied for phenotypic analysis. In the second study, twelve BDF1 mice (nine females and three males) which were F1 transgenics for the murine AGP molecule targeted to the liver via an apolipoprotein E promoter as well as four female non-transgenic littermate mice CA 022~6464 l998-ll-27 were necropsied for phenotypic analysis. In both studies, all mice were injected with BrdU one hour prior to harvest and sacrificed. Body and liver, spleen, kidney, stomach, and thymus weights were taken, blood was drawn for hematology and serum chemistries, and liver, spleen, lung, brain, heart, kidney, adrenal, stomach, small intestine, pancreas, cecum, colon, mesenteric lymph node, skin, mammary gland, trachea, esophagus, thyroid, parathyroid, salivary gland, urinary bladder, ovary or testis, uterus or seminal vesicle, bone, and bone marrow were examined were harvested for histologic analysis and BrdU labeling.
B. Histology and Histochemistry Sections of liver, spleen, lung, brain, heart, kidney, adrenal, stomach, small intestine, pancreas, cecum, colon, mesenteric lymph node, skin, mammary gland, trachea, esophagus, thyroid, parathyroid, salivary gland, urinary bladder, ovary or testis, uterus or seminal vesicle, bone, and bone marrow from AGP-1 transgenic and non-transgenic mice were fixed overnight in 10% neutral buffered zinc formalin (Anatech, Battle Creek, Michigan), paraffin embedded, sectioned at 3 ,um, and stained with hematoxylin and eosin (H&E) for routine histologic examination. In addition, sections of bone were stained for tartrate resistant acid phosphatase (TRAP) to highlight osteoclasts around bony trabeculae ln marrow spaces.
C. Immunohistochemistry Immunohistochemical staining was done on 9 ~m thick paraffin embedded sections using an automated TechMate Immunostainer (BioTek Solutions, Santa Barbara, CA). For BrdlJ immunostaining, sections were first digested with 0.1% protease (Sigma Chemical, St. ~ouis, MO) followed by 2N HCl. BrdU was detected with a rat CA 022~6464 1998-11-27 monoclonal antibody (MAb) to BrdU (Accurate Chemical, Westbury, NY) followed by a biotinylated anti-rabbit/anti-mouse secondary cocktail (BioTek) and an ABC tertiary coupled to alkaline phosphatase (BioTek). The staining reaction was visualized with BioTek Red chromagen (BioTek). For myeloperoxidase immunostaining, sections were stained with rabbit polyclonal antisera directed at human myeloperoxidase (Dako, Carpinteria, CA), followed by a biotinylated anti-rabbit/anti-mouse secondary cocktail (BioTek) and avidin-biotin complex (ABC) tertiary coupled to horseradish peroxidase. The staining reaction was visualized with diaminobenzidine (DAB, Sigma).
D. GroQ~ Pathology FindingQ
The livers from two transgenic founder mice(#s 69 and 76) and two F1 transgenic mice (#s 75-13 and 75-18) were significantly increased in size and weight (8.42 + 1.26 SD % of body weight vs. 5.33 +
0.89 SD % of body weight in non-transgenic control mice) and were pale green-tan and more friable than normal.
These four mice also had a significant increase in splenic weight (1.14 + 0.12 SD % of body weigh~ vs. 0.41 ~ 0.09 SD ~ body weight in non-transgenic control mice.
These results are summarized in Table 1.
E. Clinical Pathology Findings The four transgenic mice with enlarged livers (founder #s 69 and 76 and F1 #s 75-13 and 75-18 had marked and significant increases in total serum bilirubin and alkaline phosphatase levels, with moderate bu~ significant increases in hepatic transaminase (alanine aminotrans~erase (ALT) and aspartate aminotransferase (AST)) levels. The four transgenic mice had a mean total bilirubin level of 4.33 i 5.32 SD mg/dl while non-transgenic control mice had a CA 022~6464 1998-11-27 W O 97/46686 PCTrUS97/09895 mean total bilirubin level of 0.16 + 0.05 SD mg/dl. The mean serum alkaline phosphatase level in these four transgenic mice was 994.5 + 353.1 SD IU/l vs. 165.3 +
53.2 SD IU/l in non-transgenic control mice. The mean ALT level in these four transgenic mice was 247.3 + 89.8 SD IU/l vs. 7~.1 + 43.2 SD IU/l in non-transgenic control mice while the mean AST level in these four transgenic mice was 350.5 + 135.6 SD IU/1 vs. 132.5 +
84.9 SD IU/l in non-transgenic control mice. All of these results are summarized in table 1.
F. Histopathologic Findings H&E and BrdU stained sections of liver, spleen, lung, brain, heart, kidney, adrenal, stomach, small intestine, pancreas, cecum, colon, mesenteric lymph node, skin, mammary gland, trachea, esophagus, thyroid, parathyroid, salivary gland, urinary bladder, ovary or testis, uterus or seminal vesicle, bone, and bone marrow were examined from the 17 HE-AGP-l transgenic mice and 8 non-transgenic control littermates. Myeloperoxidase stained sections of spleen and bone marrow as well as tartrate resistant acid phosphatase (TRAP) stained sections of bone were also examined from all mice. Major histologic changes in the transgenic mice included marked periportal inflammation and bile duct hyperplasia with scattered multifocal to coalescing areas of hepatocellular necrosis in transgenic mice #s 69 and 76 (founders) and #s 75-13 and 75-18 (Fls) (Figure 3). All four of these transgenic mice also had enlarged spleens primarily due to increased red pulp myelopoiesis and to a lesser extent, lymphoid hyperplasia (Figure 4). These four transgenic mice also appeared to have increased numbers of TRAP
positive osteoclasts lining bony trabeculae in peripheral diaphyseal marrow compared to non-transgenic control mice ~Figure 5). Transgenic mice also exhibited CA 022~6464 1998-11-27 W O 97/46686 PCT~US97/09895 increased intravascular neutrophils, and small atrophic/hypoplastic uteri (only founder transgenics #s 69 and 76). The two founder transgenic mice (#s 69 and 76) also exhibited moderate peritoneal mixed inflammatory cellular infiltration.
G. Summary of Pathologic Findings in Transgenic Mice Overexpressing AGP-1 Four of the HE-AGP-1 transgenic mice (founder nos. 69 and 76 and F1 nos. 75-13 and 75-18) had relatively severe phenotypic alterations, particularly in their livers with marked cholangiohepatitis, bile duct hyperplasia and hepatic necrosis. Accompanying these hepatic histologic abnormalities in these four transgenic mice was evidence of liver dysfunction with marked elevations in total serum bilirubin and alkaline phosphatase with moderate elevations in serum transaminases. In addition to hepatic findings, these four transgenic mice also exhibited increased myelopoiesis, with a less prominent increase in circulating platelets. Founder mouse #69 had a circulating neutrophilia while all transgenic mice had a moderate increase in circulating lymphocytes. Evidence of peritoneal inflammation was also seen in the two founder transgenic mice with marked hepatic inflammation. Two of the other ~EAGP founder transgenic mice, #'s 52 and 53, also had evidence of mild cholangiohepatitis, and a mild to moderate increase in myelopoiesis and neutrophilia, suggesting that these two mice were producing the transgenic AGP-1 protein at a lower level than founder mice #s 69 and 76 were. In addition to hepatic findings, at least four of the transgenic mice exhibited a marked increase in splenic myelopoiesis and moderate lymphoid hyperplasia as well as exhibiting an apparent increase in TRAP+ osteoclasts lining bony trabeculae in the bone marrow. All of these .
findings suggest that the AGP protein plays a role in inflammation, myelopoiesis, and bone resorption (osteoclasis).
Table 1 Selected Organ Weight~ and Serum Chemi~trie~ in HE-AGP-1 Tran~genic Mice HEAGP Non- p value Transgenic transgenic Mice ~n=4) Mice (n=8) Li~er Weight as 8.42 + 1.26 SD 5.33 + 0.89 0.0006 % of Body Weight SD
Spleen Weight as 1.14 + 0.12 SD 0.41 + 0.09 <0.0001 % Body Weight SD
Total Bilirubin 4.33 + 5.32 SD 0.16 + 0.05 0.04 (mg/dl) SD
Alkaline 994.5 + 353.1 165.3 + 53.2 <0.0001 Phosphatase SD SD
(IU/l) Alanine 247.3 + 89.8 SD 78.1 + 43.2 0.001 Aminotran~ferase SD
~ALT) (IU/l) Aspartate 350.5 + 135.6 132.5 + 84.9 0.006 Aminotransferase SD SD
(AST) (IU/l) CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 SEQUENCE LISTING
(1) GENERAL INFORMATION:
~i) APPLICANT: Johnson, Merrie Jo Simonet, William S.
Danilenko, Dimitry M.
(ii) TITLE OF INVENTION: TUMOR NECROSIS FACTOR-RELATED
POLYPEPTIDE
(iii) NUMBER OF SEQUENCES: 15 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Amgen Inc.
(B) STREET: 1840 Dehavilland Drive (C) CITY: Thousand Oaks (D) STATE: California (E) COUNTRY: U.S.A.
(F) ZIP: 91320 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Winter, Robert B.
(C) REFERENCE/DOCKET NUMBER: A-410 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3048 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 245..1120 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 ~ 31 -GACCl-ClCA GGCACTGCTG CTGGGCTGCA AGTCTGCATT GGGAAGTCAG ACCTGGACAG 240 Met Pro Ser Ser Gly Ala Leu Lys Asp Leu Ser Phe Ser Gln His Phe Arg Met Met Val Ile Cys Ile Val Leu Leu Gln Val Leu Leu Gln Ala Val Ser Val Ala Val Thr Tyr Met Tyr Phe Thr Asn Glu Met Lys 20 Gln Leu Gln Asp Asn Tyr Ser Lys Ile Gly Leu Ala Cys Phe Ser Lys Thr Asp Glu Asp Phe Trp Asp Ser Thr Asp Gly Glu Ile Leu Asn Arg Pro Cys Leu Gln Val Lys Arg Gln Leu Tyr Gln Leu Ile Glu Glu Val Thr Leu Arg Thr Phe Gln Asp Thr Ile Ser Thr Val Pro Glu Lys Gln Leu Ser Thr Pro Pro Leu Pro Arg Gly Gly Arg Pro Gln Lys Val Ala 40 Ala His Ile Thr Gly Ile Thr Arg Arg Ser Asn Ser Ala Leu Ile Pro Ile Ser Lys Asp Gly Lys Thr Leu Gly Gln Lys Ile Glu Ser Trp Glu Ser Ser Arg Lys Gly His Ser Phe Leu Asn His Val Leu Phe Arg Asn Gly Glu Leu Val Ile Glu Gln Glu Gly Leu Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe Gln Glu Ala Glu Asp Ala Ser Lys Met Val Ser CA 022~6464 1998-11-27 W 0 97/46686 PCTrUS97/09895 Lys Asp Lys Val Arg Thr Lys Gln Leu Val Gln Tyr Ile Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Val Leu Met Lys Ser Ala Arg Asn Ser 0 Cys Trp Ser Arg Asp Ala Glu Tyr Gly Leu Tyr Ser Ile Tyr Gln Gly Gly Leu Phe Glu Leu Lys Lys Asn Asp Arg Ile Phe Val Ser Val Thr Asn Glu His Leu Met Asp Leu Asp Gln Glu Ala Ser Phe Phe Gly Ala Phe Leu Ile Asn *
CA 022~6464 l998-ll-27 TCCACCTACC AAGATGTTGA ACA~ C TTTTTAAGAT ~1lGG1GCCl GGAGTTTCAT 2360 TAGAGTAACA CAAAACTAAC TAAAACCAAA CAACTCCAAA GGAGCCCATA TGIGl.l.AA 2420 TGAAACATTT TTTAAGCCTA TTGGGGGCCT ~AAGAGATTG CTCAGAGGAA AACAGCACTT 2480 CATTCTGACA AAATATATCC ATACACAAAA GTA~ l AAAAGCTTAT TTGAATGTAA 2660 ~2) INFORMATION FOR SEQ ID No:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 292 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Met Pro Ser Ser Gly Ala Leu Lys Asp Leu Ser Phe Ser Gln His Phe Arg Met Met Val Ile Cys Ile Val Leu Leu Gln Val Leu Leu Gln Ala Val Ser Val Ala Val Thr Tyr Met Tyr Phe Thr Asn Glu Met Lys Gln Leu Gln Asp Asn Tyr Ser Lys Ile Gly Leu Ala Cys Phe Ser Lys Thr Asp Glu Asp Phe Trp Asp Ser Thr Asp Gly Glu Ile Leu Asn Arg Pro CA 022~6464 l998-ll-27 ~ 39 -Cys Leu Gln Val Lys Arg Gln Leu Tyr Gln Leu Ile Glu Glu Val Thr Leu Arg Thr Phe Gln Asp Thr Ile Ser Thr Val Pro Glu Lys Gln Leu Ser Thr Pro Pro Leu Pro Arg Gly Gly Arg Pro Gln Lys Val Ala Ala His Ile Thr Gly Ile Thr Arg Arg Ser Asn Ser Ala Leu Ile Pro Ile Ser Lys Asp Gly Lys Thr Leu Gly Gln Lys Ile Glu Ser Trp Glu Ser Ser Arg Lys Gly His Ser Phe Leu Asn His Val Leu Phe Arg Asn Gly Glu Leu Val Ile Glu Gln Glu Gly Leu Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe Gln Glu Ala Glu Asp Ala Ser Lys Met Val Ser Lys Asp Lys Val Arg Thr Lys Gln Leu Val Gln Tyr Ile Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Val Leu Met Lys Ser Ala Arg Asn Ser Cys Trp Ser Arg Asp Ala Glu Tyr Gly Leu Tyr Ser Ile Tyr Gln Gly Gly Leu Phe Glu Leu Lys Lys Asn Asp Arg Ile Phe Val Ser Val Thr Asn Glu His Leu Met Asp Leu Asp Gln Glu Ala Ser Phe Phe Gly Ala Phe Leu Ile Asn *
(2) INFORMATION FOR SEQ ID NO:3:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1060 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 35..880 CA 022~6464 l998-ll-27 W O 97/46686 PCT~US97/09895 ~xi) SL~UENCE DESCRIPTION: SEQ ID NO:3:
Met Ala Met Met Glu Val Gln Gly Gly Pro Ser Leu Gly Gln Thr Cys Val Leu Ile Val Ile Phe Thr Val Leu Leu Gln Ser Leu Cys Val Ala Val Thr Tyr Val Tyr Phe Thr Asn Glu Leu Lys Gln Met Gln Asp Lys Tyr Ser Lys Ser Gly Ile 20 Ala Cys Phe Leu Lys Glu Asp Asp Ser Tyr Trp Asp Pro Asn Asp Glu Glu Ser Met Asn Ser Pro Cys Trp Gln Val Lys Trp Gln Leu Arg Gln Leu Val Arg Lys Met Ile Leu Arg Thr Ser Glu Glu Thr Ile Ser Thr Val Gln Glu Lys Gln Gln Asn Ile Ser Pro Leu Val Arg Glu Arg Gly Pro Gln Arg Val Ala Ala His Ile Thr Gly Thr Arg Gly Arg Ser Asn 40 Thr Leu Ser Ser Pro Asn Ser Lys Asn Glu Lys Ala Leu Gly Arg Lys Ile Asn Ser Trp Glu Ser Ser Arg Ser Gly His Ser Phe Leu Ser Asn Leu His Leu Arg Asn Gly Glu Leu Val Ile His Glu Lys Gly Phe Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe Gln Glu Glu Ile Lys Glu Asn Thr Lys Asn Asp Lys Gln Met Val Gln Tyr Ile Tyr Lys Tyr Thr CA 022~6464 l998-ll-27 W O 97/46686 PCT~US97/09895 Ser Tyr Pro Asp Pro Ile Leu Leu Met Lys Ser Ala Arg Asn Ser Cys Trp Ser Lys Asp Ala Glu Tyr Gly Leu Tyr Ser Ile Tyr Gln Gly Gly 10 Ile Phe Glu Leu Lys Glu Asn Asp Arg Ile Phe Val Ser Val Thr Asn Glu His Leu Ile Asp Met Asp His Glu Ala Ser Phe Phe Gly Ala Phe Leu Val Gly *
CAGAAAACAG AAAACAAAAA AACCTCTATG CAATCTGAGT AGAGCAGCcA CAACCAAAAT 1040 (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 282 amino acids (L) TYPE: amino acid ~D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Met Ala Met Met Glu Val Gln Gly Gly Pro Ser Leu Gly Gln Thr Cys Val Leu Ile Val Ile Phe Thr Val Leu Leu Gln Ser Leu Cys Val Ala Val Thr Tyr Val Tyr Phe Thr Asn Glu Leu Lys Gln Met Gln Asp Lys Tyr Ser Lys Ser Gly Ile Ala Cys Phe Leu Lys Glu Asp Asp Ser Tyr Trp Asp Pro Asn Asp Glu Glu Ser Met Asn Ser Pro Cys Trp Gln Val Lys Trp Gln Leu Arg Gln Leu Val Arg Lys Met Ile Leu Arg Thr Ser Glu Glu Thr Ile Ser Thr Val Gln Glu Lys Gln Gln Asn Ile Ser Pro CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 ~ 37 -Leu Val Arg Glu Arg Gly Pro Gln Arg Val Ala Ala His Ile Thr Gly 5 Thr Arg Gly Arg Ser Asn Thr Leu Ser Ser Pro Asn Ser Lys Asn Glu Lys Ala Leu Gly Arg Lys Ile Asn Ser Trp Glu Ser Ser Arg Ser Gly His Ser Phe Leu Ser Asn Leu His Leu Arg Asn Gly Glu Leu Val Ile His Glu Lys Gly Phe Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe Gln Glu Glu Ile Lys Glu Asn Thr Lys Asn Asp Lys Gln Met Val Gln Tyr Ile Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Leu Leu Met Lys Ser Ala Arg Asn Ser Cys Trp Ser Lys Asp Ala Glu Tyr Gly Leu Tyr Ser Ile Tyr Gln Gly Gly Ile Phe Glu Leu Lys Glu Asn Asp Arg Ile Phe Val Ser Val Thr Asn Glu His Leu Ile Asp Met Asp His Glu Ala Ser Phe Phe Gly Ala Phe Leu Val Gly *
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
~A) LENGTH: 12 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: slngle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
CGGACGCGTG GG
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
CA 022~6464 l998-ll-27 W O 97/46686 P ~ rusg7/og895 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
(2) INFORMATION FOR SEQ ID NO:ll:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TopoLoGy: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:ll:
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
CA 022~6464 l998-ll-27 ~2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
(2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
Fiel~ of the Invention The invention relates to AGP-1, a tumor necrosis factor-related polypeptide involved in inflammation, myelopoiesis and bone resorption. Nucleic acid sequences, vectors and host cells for the expression of AGP-1 are disclosed. Also encompassed are pharmaceutical compositions comprising AGP-l, methods of identifying antagonists of AGP-l and methods of treatment using AGP-1 or AGP-1 antagonists.
Background of the Invention The tumor necrosis factor family is a growing group of cytokines which function as mediators of immune regulation, acute and chronic inflammatory responses, and programmed cell death. Tumor necrosis factor (TNFa) is the prototypical member of this family which also includes lymphotoxin (LTa/ TNF~), lymphotoxin ~ (LT~), and ligands for CD27, CD30, CD40, OX40, 4-lBB, and Fas.
Homology among these family members is confined to the carboxy-terminal 150 amino acid residues, with the highest degree of homology within the ~-strand regions involved in subunit contacts which lead to oligomerization. With the exception of LTa, which is a secreted protein, all the ligands in this family are type II membrane proteins. The homologous carboxy-terminal domains are extracellular, and the shorter non-homologous amino-terminal regions are intracellular. The membrane bound form of TNFa can be the target of proteolytic cleavage, generating a soluble form of TNFa which circulates in certain disease states.
CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 As systemic delivery of TNFa induces toxic shock and widespread tissue necrosis, TNFa may contribute to the morbidity and mortality associated with a variety of infectious diseases, including septic shock, autoimmune disorders and graft-versus-host disease.
The TNF family of cytokines exert their biological effects through their interactions with a family of receptors which are generally characterized as Type I membrane proteins with cysteine-rich pseudorepeats in their extracellular domains. Of the twelve TNF receptor superfamily members identified to date, only the two poxvirus genes, T2 and A53R, encode soluble, secreted receptors. Whereas soluble forms of TNFa play an important role in the immune response, the interaction of membrane bound ligands and receptors of this family, particularly on T and B cells, likely plays a major role in cell-cell cross-talk within the immune system. In this regard, signaling through FasL and its receptor is believed to play an important role in T-cell mediated cytotoxicity.
Perhaps the most intriguing activity associated with this family is their ability to induce programmed cell death through the apoptotic pathway, a phenomena which is crucial in many areas of vertebrae development, including T-cell development. Of the known TNF family members, TNFa, LTa and FasL have all been demonstrated to induce apoptosis of certain cells under the correct conditions. Although the apoptotic effects of TNFa and LTa appear to be limited to a minimal number of cell types, signalling through Fas has been demonstrated to induce apoptosis of numerous transformed cell lines and chronically activated T cell clones.
Additionally, two mutations that accelerate autoimmune disease (lpr and gld), resulting in lymphadenopathy and splenomegaly in mutant mice, are known to correspond to CA 022~6464 1998-11-27 W O 97146686 PCT~US97/09895 mutations within the genes encoding Fas and FasL, respectively.
In view of the involvement of TNF and TNF-related family members in conditions associated with inflammation, infectious disease, immune system disorders and apoptotic cell death, it is desirable to identify additional related TNF family members.
It is an object of this invention to identify TNF-related molecules for the purpose of developing treatments for disorders related to TNF and TNF-related molecules.
A novel gene has been identified which encodes a polypeptide having significant homology to the TNF
family member FasL. The polypeptide has been termed AGP-1. Transgenic mice expressing murine AGP-1 in the liver exhibit hepatic inflammation and necrosis, bile duct hyperplasia, as well as pathological findings supportive of direct or indirect systemic effects of the factor. The nucleotide and amino acid sequence of AGP-1 was found to be identical to the sequence reported for TNF-related apoptosis-inducing ligand (TRAIL, see Wiley et al. Immunity 3, 673-682 (1995)). TRAIL was observed to induce apoptosis in a wide variety of transformed cell lines.
Summary of the Invention A novel member of the tumor necrosis factor family, termed AGP-1, has been identified from a murine cDNA library and expressed in a transgenic mouse system.
AGP-l is involved in myelopoiesis accompanied by an increase in neutrophils and lymphocytes, inflammation and necrosis of the liver, and bone resorption. Human AGP-1 has also been identified.
The invention provides for nucleic acids encoding a polypeptide having at least one of the CA 022~6464 1998-11-27 W 097/46686 PCTrUS97/09895 biological activities of AGP-1, vectors and host cells expressing the polypeptide, and method for producing recombinant AGP-1. Antibodies or fragments thereof which specifically bind AGP-1 are also provided.
Methods of identifying antagonists of AGP-l which reduce or eliminate at least one of the biological activities of AGP-1 are also encompassed by the invention. Such antagonists include peptides, proteins, carbohydrates or small molecular weight organic molecules which bind to AGP-l or to its receptor(s) and interfere with AGP-1 receptor activation.
AGP-1 may be used to treat hematopoeitic disorders characterized by a decrease in cell population of the bone marrow. AGP-1 antagonists may be used to treat inflammatory conditions. AGP-1 antagonists may also be used to treat bone disorders resulting from an increase in bone resorption. Pharmaceutical compositions comprising AGP-1 and AGP-l antagonists are also encompassed by the invention.
Description of the Figures ~ igure 1. cDNA and amino acid sequence of murine AGP-1.
Figure 2. cDNA and amino acid sequence of human AGP-1.
Figure 3. Hematoxylin and Eosin (H&E) stained sections of liver from non-transgenic mouse #12 (A) and HEAGP F1 transgenic mouse #75-13 (B). B illustrates marked proliferative cholangiohepatitis characterized by periportal bile duct hyperplasia and inflammation (arrowheads in B; arrowhead in A points to a normal portal tract for contrast) with scattered foci of hepatocellular necrosis (asterisk in A). Bars = 50 ~m.
CA 022~6464 l998-ll-27 W 097/46686 PCTrUS97/09895 Figure 4. Myeloperoxidase stained sections of HEAGP F1 transgenic (B - mouse #75-13) and non-transgenic (A mouse #12) spleen. B illustrates splenomegaly in the transgenic mouse primarily caused by an expanded red pulp (asterisks) due to increased red pulp myelopoiesis (arrowheads in B illustrate aggregates of myeloperoxidase positive myeloid precursors) in the transgenic spleen as well as by white pulp lymphoid hyperplasia (arrows in B vs. A). Bars = 250 ~m.
Figure 5. TRAP stained sections of bone marrow from a non-transgenic control mouse (A - mouse #12) and an HEAGP F1 transgenic mouse (mouse #75-13) illustrating an apparent increase in the number of TRAP+ osteoclasts (arrows) lining bony trabeculae in the transgenic bone marrow (B) vs. the non-transgenic marrow (A). Bars =
25 ~m.
Detailed Description of the Invention The invention provides for a novel member of the TNF receptor superfamily, termed AGP-1. AGP-1 refers to a polypeptide having an amino acid sequence of mammalian AGP-1 or a derivative thereof and having at least one of the biological activities of AGP-l. In preferred embodiments, AGP-1 is mouse or human AGP-l.
cDNA and amino acid sequences of mouse and human AGP-1 are shown in Figures 1 and 2, respectively. The biological activities of AGP-1 include, but are not limited to, involvement in myelopoiesis, inflammation and necrosis, especially in the liver, and bone resorption.
The invention provides for isolated nucleic acids encoding polypeptides having one or more of the biological properties of AGP-l. As used herein, the CA 022~6464 1998-11-27 term nucleic acid represents cDNA, genomic DNA, wholly or partially synthetic DNA or RNA. The nucleic acids of the invention are selected from the group consisting of:
a) the nucleic acids as shown in Figure 1 (SEQ ID NO: 1) or Figure 2 (SEQ ID NO: 3);
b) nucleic acids which hybridize to the polypeptide coding regions of the nucleic acids shown in Figure 1 (SEQ ID NO: 1) or Figure 2 (SEQ ID NO: 3) and remain hybridized to the nucleic acids under high stringency conditions; and c) nucleic acids which are degenerate to the nucleic acids of (a) or (b).
Nucleic acid hybridizations typically involve a multi-step process comprising a first hybridization step to form nucleic acid duplexes from single strands followed by a second hybridization step carried out under more stringent conditions to selectively retain nucleic acid duplexes having a degree of homology which depends upon the stringency of hybridization during the second step. The conditions of the first hybridization step are generally not crucial, provided they are not of higher stringency than the second hybridization step.
Generally, the second hybridization is carried out under conditions of high stringency, wherein "high stringency"
conditions refers to conditions of temperature and salt which are about 12-20~C below the melting temperature (Tm) of a perfect hybrid of part or all of the complementary strands corresponding to SEQ. ID. NO: 1 or, alternatively, are about 12-20~C below the Tm Of a perfect hybrid of part or all of the complementary strands corresponding to SEQ. ID. NO: 3. In one embodiment, "high stringency" conditions refer to conditions of about 65~C and not more than about lM Nat.
It is understood that salt concentration, temperature and/or length of incubation may be varied in either the first or second hybridization steps such that one CA 022~6464 1998-11-27 W O 97/46686 PCTrUS97/09895 obtains the hybridizing nucleic acid molecules according to the invention. Conditions for hybridization of nucleic acids and calculations of Tm for nucleic acid hybrids are described in Sambrook et al. Molecular Cloninq: A Tl~horatory Manu~l Cold Spring Harbor Laboratory Press, New York. (1989).
The nucleic acids of the invention may hybridize to part or all of the polypeptide coding regions of AGP-l as shown in SEQ ID NO: 1 and SEQ ID NO:
3, and therefore may be truncations or extensions of the nucleic acids in SEQ ID NO: 1 and SEQ ID NO: 3.
Truncated or extended nucleic acids are encompassed by the invention provided that they retain one or more of the biological properties of AGP-1, such as stimulating myelopoiesis, bone resorption or an inflammatory response. In one embodiment, the nucleic acid will encode a polypeptide of at least about 10 amino acids.
In another embodiment, the nucleic acid will encode a polypeptide of at least about 20 amino acids. In yet another embodiment, the nucleic acid will encode polypeptides of at least about 50 amino acids. The hybridizing nucleic acids may also include noncoding sequences located 5' and/or 3' to the AGP-1 coding regions. Noncoding sequences include regulatory regions involved in AGP-1 expression, such as promoters, enhancer regions, translational initiation sites, transcription termination sites and the like.
In preferred embodiments, the nucleic acids of the invention encode mouse AGP-1 or human AGP-1. Mouse AGP-1 is shown in Figure 1 and SEQ. ID. NO: 2 and human AGP-1 is shown in Figure 2 and SEQ. ID. NO: 4. Nucleic acids may encode a full-length form of AGP-1 which is a membrane-bound or soluble forms of AGP-1 lacking part or all of the transmembrane region. The predicted transmembrane region for human AGP-1 includes residues 16-36 as shown in S~Q. ID. NO: 4. Deletions of part or CA 022~6464 1998-11-27 all these residues would be expected to produce soluble forms of AGP-1.
The nucleic acids of the invention will be linked with DNA sequences so as to express biologically active AGP-l. Sequences required for expression are known to those skilled in the art and include promoters and enhancer sequences for initiation of RNA synthesis, transcription termination sites, ribosome binding sites for the initiation of protein synthesis, and leader sequences for secretion. Sequences directing expression and secretion of AGP-1 may be homologous, i.e., those sequences in the genome involved in AGP-1 expression and secretion, or may be heterologous. A variety of plasmid vectors are available for expressing AGP-1 in host cells. One example is plasmid pDSR~ described in PCT Application No. 90/14363 which may be used for expression in mammalian hosts. AGP-l coding regions may also be modified by substitution of preferred codons for optimal expression in a given host. Codon usage in bacterial, plant, insect and mammalian host systems is known and may be exploited by one skilled in the art to optimize mRNA translation. In addition, vectors are available for the tissue-specific expression of AGP-1 in transgenic animals. Retroviral and adenovirus-based gene transfer vectors may also be used for the expression of AGP-l in human cells for in vivo therapy (see PCT Application No. 86/00922).
Procaryotic and eucaryotic host cells expressing AGP-1 are also provided by the invention.
Host cells include bacterial, yeast, pl-ant, insect or mammalian cells. AGP-1 may also be produced in transgenic animals such as mice or goats. Plasmids and vectors containing the nucleic acids of the invention are introduced into appropriate host cells using transfection or transformation techniques known to one skilled in the art. Host cells may contain DNA
CA 022~6464 1998-11-27 W O 97/46686 PCTrUS97/09895 g _ sequences encoding the full-length AGP-l gene as shown in Figure 1. Host cells will also process AGP-1 encoded by the full-length gene to the mature form or produce the mature form without processing by expression of DNA
sequences encoding same. Examples of mammalian host cells for AGP-1 expression include, but are not limited to COS, CHOd-, 293 and 3T3 cells.
The invention also provides AGP-1 as the product of procaryotic or eucaryotic expression of an exogenous DNA sequence, i.e., AGP-1 is recombinant AGP-1. Exogenous DNA sequences include cDNA, genomic DNA and synthetic DNA sequences. AGP-1 may be the product of bacterial, yeast, plant, insect or mammalian cells expression. AGP-1 produced in bacterial cells will have an N-terminal methionine residue. The invention also provides for a process of producing AGP-1 comprising growing procaryotic or eucaryotic host cells transformed or transfected with nucleic acids encoding AGP-1 and isolating polypeptide expression products of the nucleic acids.
Polypeptides which are mamalian AGP-1 or are derivatives thereof are encompassed by the invention. A
derivative of AGP-1 refers to a polypeptide having an addition, deletion, insertion or substitution of one or more amino ac~ds such that the resulting polypeptide has at least one of the biological activities of AGP-l. The derivative may be naturally occurring, such as a polypeptide product of an allelic variant or a mRNA
splice variant:, or it may be constructed using techniques available to one skilled in the art for manipulating and synthesizing nucleic acids.
AGP-1 polypeptides may be full-length polypeptides or fragments thereof which, in preferred embodiments, are at least about ten amino acids, at _ CA 022~6464 1998-11-27 W O 97146686 PCTrUS97/09895 least about 20 amino acids, or at least about 50 amino acids in length. AGP-1 full-length polypeptides and fragments preferably have the amino acid sequence in Figure 1 or 2 or a portion thereof. The polypeptides may or may not have an amino terminal methionine residue.
Also included in the invention are AGP-1 polypeptides which have undergone post-translational modifications (e.g., addition of N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition of an N-terminal methionine residue as a result of procaryotic host cell expression. As mouse and human AGP-1 are encoded as transmembrane proteins, soluble forms of AGP-1 are also envisioned. Such soluble forms may be readily constructed by removal of the transmembrane region of the polypeptide. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.
AGP-1 chimeric proteins comprising part or all of an AGP-1 amino acid sequence fused to a heterologous amino acid sequence are also included. The heterologous sequence may be any sequence which allows the resulting fusion protein to retain the activity of AGP-1. The heterologous sequences include, for example, immunoglobulin fusions, such as an Fc region of IgG, which provide dimerization, or fusions to enzymes which provide a label for the polypeptide.
The polypeptides of the invention are isolated and purified from tissues and cell lines which express AGP-1 and from transformed host cells expressing AGP-1, or purified from cell cultures containing the secreted protein. Isolated AGP-1 polypeptide is free from CA 022~6464 1998-11-27 W O 97/46686 PCT~US97/09895 association with human proteins and other cell constituents.
Also provided by the invention are chemically modified derivatives of AGP-1 which provide additional advantages such as increased stability, longer circulating time, or decreased immunogenicity (see for example U.S. Patent No. 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.
A method for the purification of AGP-1 from natural sources (e.g. tissues and cell lines which normally express AGP-1) and from transfected host cells is also encompassed by the invention. The purification process may employ one or more standard protein purification steps in an appropriate order to obtain purified protein. The chromatography steps can include ion exchange, gel filtration, hydrophobic interaction, reverse phase, chromatofocusing, affinity chromatography employing an anti-AGP-1 antibody or biotin-streptavidin affinity complex and the like.
The invention also encompasses AGP-1 antagonists and the methods for obtaining them. An antagonist will reduce or eliminate one or more of the biological activities of AGP-1. As examples, an AGP-1 antagonist may act as an anti-inflammatory agent, or may act to inhibit bone-resorption. AGP-1 antagonists include substances which bind to AGP-1 or to AGP-1 receptors in a manner to prevent normal ligand-receptor interaction and substances which regulate the expression CA 022~6464 1998-11-27 W 097/46686 PCT~US97109895 - 12 -of AGP-1. Substances which bind to AGP-1 or to AGP-1 receptors include proteins, peptides, carbohydrates and small molecular weight organic compounds. Examples of protein inhibitors include anti-AGP-l antibodies, anti-AGP-1 receptor antibodies and soluble forms of AGP-1 receptor comprising part or all of the extraceullular domain of the AGP-1 receptor. Substances which regulate AGP-1 expression typically include nucleic acids which are complementary to nucleic acids encoding AGP-1 or AGP-1 receptors and which act as anti-sense regulators of expression.
Methods for indentifying compounds which interact with AGP-l are also encompassed by the invention. The method comprises incubating AGP-1 with a compound under conditions which permit binding of the compound to AGP-1 and measuring the extent of binding.
The compound may be substantially purlfied or present in a crude mixture. Binding compounds may be proteins, peptides, carbohydrates or small molecular weight organic compounds. The compounds may be further characterized by their ability to enhance or reduce AGP-1 biological activity and therefore act as AGP-l agonists or as AGP-1 antagonists. Preferably, the method is used to identify AGP-1 antagonists.
Antibodies specifically binding the AGP-1 polypeptides of the invention are also encompassed by the invention. The antibodies may be produced by immunization with full-length membrane-bound AGP-1, soluble AGP-1, or a peptide fragment thereof, and the antibodies may be polyclonal or monoclonal. In addition, the antibodies of the invention may be recombinant, such as chimeric antibodies wherein the murine constant regions on light and heavy chains are replaced by human sequences, or CDR-grafted antibodies wherein only the complementary determining regions are CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 of murine origin. Antibodies of the invention may also be human antibodies prepared, for example, by immunizatlon of transgenic animals capable of producing human antibodies (see, for example, PCT Application No. WO93/12227). The antibodies are useful for detecting AGP-1 in biological samples, thereby allowing the identification of cells or tissues which produce AGP-1. In addition, antibodies which bind to AGP-1 and prevent receptor interaction may also be useful for blocking the effects of AGP-1.
The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of the AGP-1 polypeptide of the invention together with a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and/or adjuvant. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an AGP-1 antagonist. The term "therapeutically effective amount" means an amount which provides a therapeutic effect for a specified condition and route of administration. The composition may be in a liquid or lyophilized form and comprises a diluent (Tris, acetate or phosphate buffers) having various pH
values and ionic strengths, solubilizer such as Tween or Polysorbate, carriers such as human serum albumin or gelatin, preservatives such as thimerosal or benzyl alcohol, and antioxidants such as ascrobic acid or sodium metabisulfite. Also encompassed are compositions comprising AGP-1 modified with water soluble polymers to increase solubility, stability, plasma half-life and bioavailability. Compositions may also comprise incorporation of AGP-1 into liposomes, microemulsions, micelles or vesicles for controlled delivery over an extended period of time. Selection of a particular composition will depend upon a number of factors, _ .
CA 022~6464 l998-ll-27 W 097/46686 PCT~US97/09895 including the condition being treated, the route of administration and the pharmacokinetic parameters desired. A more extensive survey of component suitable for pharmaceutical compositions is found in Remington's Pharmaceutical Sciences, 18th ed. A.R. Gennaro, ed.
Mack, Easton, PA (1980).
Compositions of the invention may be administered by injection, either subcutaneous, intravenous or intramuscular, or by oral, nasal, pulmonary or rectal administration. The route of administration eventually chosen will depend upon a number of factors and may be ascertained by one skilled in the art.
The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of the nucleic acids of the invention together with a pharmaceutically acceptable adjuvant. Nucleic acid compositions will be suitable for the delivery of part or all of the APG-l coding region and/or flanking regions to cells and tissues as part of an anti-sense therapy regimen.
Hepatic expression of AGP-l in transgenic mice resulted in marked myelopoiesis accompanied by an increase in neutrophils and lymphocytes. Therefore, AGP-l may be used to treat hematopoietic disorders that are associated with a decrease in the population of cells in bone marrow. In particular, AGP-l may be used to treat conditions resulting in low white blood cell levels, particularly reduced levels of neutrophils and lymphocytes. Such conditions may result from disease, injury or exposure to certain environmental agents known to suppress bone marrow levels. It is understood that AGP-l may be administered alone or in combination with other factors to treat hematopoietic disorders. In one embodiment, AGP-l is used in conjunction with a CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 therapeutically effective amount of a factor which stimulates hematopoiesis. Such factors include erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF), megakaryocyte growth and differentiation factor (MGDF), granulocyte-macrophage stimulating factor (GM-CSF), stem cell factor (SCF), interleukin-3 (IL-3) and interleukin-6 (IL-6).
Hepatic expression of AGP-l in transgenic mice resulted in increased inflammation and necrosis, especially in the liver. This effect may be the result of a high local concentration of AGP-l occurring in the liver during transgene expression. Thus, antagonists of AGP-l may be used as anti-inflammatory agents which are administered to patients susceptible to or suffering from an inflammatory condition. Inflammatory conditions include rhematoid arthritis, systemic lupus erythematosis, psoriasis, systemic and localized amyloidosis, Sjogerns syndrome, sclerodoma, dermatomyositls, glomerulonephritis, and inflammation arising from infections and parasitic diseass. AGP-l antagonists which reduce or eliminate inflammation may be administered alone or in combination with a therapeutically effective amount of an anti-inflammtory agent such as a corticosteroid, a non-steroidal anti-inflammatory agent (NSAID), or cyclosporin A.
AGP-l antagonists may also reduce or eliminate necrosis associated with an inflammatory condition.
AGP-l is also involved in stimulation of osteoclasts which promote bone resorption through mineralization of the bone matrix. Increase in bone resorption rates that exceed rates of bone formation can lead to various bone disorders including osteoporosis, osteomyelitis, hypercalcemia, osteopenia brought on by surgery or steroid administration, Paget's disease, osteonecrosis, bone loss due to rheumatoid arthritis, periodontal bone loss, and osteolytic metastasis.
CA 022~6464 l998-ll-27 W O 97146686 PCTrUS97/09895 Antagonists of AGP-1 may be administered to patients suffering from disorders brought on by increased osteoclast activity and increased bone resorption.
AGP-1 antagonists may be administered alone or in c~mbination with a therapeutically effective amount a bone growth promoting agent including bone morphogenic factors designated BMP-1 to BMP-12, transforming growth factor-~ and TGF-~ family members, interleukin-1 inhibitors, TNF~ inhibitors, parathyroid hormone, E series prostaglandins, bisphosphonates and bone-enhancing minerals such as fluoride and calcium.
The following examples are offered to more fully illustrate the invention, but are not construed as limiting the scope thereof.
Identification and Isolation of Murine and Human AGP-1 Genes A. Murine AGP-1 Materials and method for cDNA cloning and analysis are described in Sambrook et.al. Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989). A cDNA library was constructed using mRNA isolated from 5, 6, and 7 day post-5FU
treated bone marrow from C57/B6 female mice. Mice were treated with 150mg/kg 5-fluorouracil (5FU), intraperitoneally, on each of three consecutive days.
On day 5, 6, and 7 post-5FU treatment both femurs and tibias were harvested, and plugs flushed with PBS.
Bones were crushed with mortar and pestle and combined with the bone marrow plugs. The poly A+ mRNA was purified using Fast Track mRNA Kit (InVitrogen, San Diego, CA) using the manufacturer's recommended CA 022~6464 1998-11-27 W097/46686 PCT~S97/09895 procedures. A random primed cDNA library was prepared using the Superscript Plasmid System (Gibco BRL, Gaithersburg, MD). A random cDNA primer containing an internal Not I restriction site was used to initiate first strand synthesis and had the following double strand sequence:
5'-CCTCTGCGGCCGCTACANNNNNNNNT-3' (SEQ lD NO: 5) 3'-pGGAGACGCCG~CGA-5' (SEQ ID NO: 6) The first strand cDNA synthesis reaction was assembled using l~g of the mRNA and 150 ng of the Not 1 random primer. After second strand synthesis, the reaction products were extracted with the phenol:chloroform:isoamyl alcohol mixture and ethanol precipitated. The double strand (ds) cDNA products were ligated to the following ds oligonucleotide adapter (Gibco BRL):
5'-TCGACCCACGCGTCCG-3' (SEQ ID NO: 7) 3'-GGGTGCGCAGGCp-5' (SEQ ID NO: 8~
After ligation the cDNA was digested to completion with Not 1, extracted with phenol:chloroform:isoamyl alcohol (25:24:1 ratio) and ethanol precipitated. The resuspended cDNA was then size fractionated by gel filtration using the premade columns provided with the Superscript Plasmid System (Gibco BRL) as recommended by the manufacturer. The fractions containing the largest cDNA products were ethanol precipitated and then directionally ligated into Not 1 and Sal 1 digested pMOB vector DNA (Strathmann et.
al. Science 252, 802-808 (1991)). The ligated cDNA was introduced into electrocompetent XL1-Blue E. coli (Stratagene, I,aJolla, CA) by electroporation.
Approximately 20,000 colonies were picked and arrayed into 96 well microtiter plates containing 200 ~l of CA 022~6464 1998-11-27 W O 97/46686 PCT~US97/09895 L-broth, 7.5% glycerol, 50 ~g/ml ampicillin and 12.5~g/ml tetracycline. The cultures were grown overnight at 37 C, a duplicate set of microtiter plates were made using a sterile 96 pin replicating tool, then both sets were stored at -80 C for further analysis.
To sequence random murine 5FU-treated bone marrow cDNA clones, sequencing template was prepared by PCR amplification of cloned cDNA inserts using vector primers. Glycerol stocks of cDNA clones were thawed, and small aliquots were diluted 1:25 in distilled water.
Approximately 3.0 ~l of diluted bacterial cultures were added to PCR reaction mixture (Boehringer-Mannheim) containing the following oligonucleotides:
5' TGTAAAACGACGGCCAGT 3' (SEQ ID NO: 9) 5' CAGGAAACAGCTATGACC 3' (SEQ ID NO: 10) The reactions were incubated in a thermocycler (Perkin-Elmer 9600) with the following cycle conditions:
94 C for 2 minutes; 94 C for 5 seconds, 50 C for 5 seconds and 72 C for 3 minutes for 30 cycles and then a final extension at 72 C for 4 mlnutes. After incubation in the thermocycler, the reactions were diluted with 2.0 ml of water. The amplified DNA
fagments were further purified using Centricon columns (Princeton Separations) using the manufacturer's recommended procedures. In some instances, low primer and deoxynucleoside triphosphate concentrations were used in the amplification reactions, and in those instances, Centricon purification was not necessary.
The PCR reaction products were sequenced on an Applied Biosystems 373A automated DNA sequencer using T3 primer:
5'-CAATTAACCCTCACTAAAGG-3' (SEQ ID NO: 11) CA 022~6464 1998-11-27 W O 97/46686 PCTrUS97/09895 Taq dye-terminator reactions (Applied Biosystems) following the manufacturer's recommended procedures.
The resulting 5' nucleotide sequence obtained from randomly picked cDNA clones were translated and then compared to the existing database of known protein sequences using a modified version of the FASTA program (Pearson, et. al. Meth. Enzymol. 183, 63-98 (199~)).
Translated sequences were also analyzed for the presence of specific tumor necrosis factor superfamily motifs, using the sequence profile method of Gribskov, et. al.
(Proc. Natl. Acad. Sci. USA 83, 4355-4359 (1987)) as modified by Ll~ethy et al. (Protein Science 3, 139-146 (1994)).
Using the FASTA and Profile search data, an EST designated muAGP-EST1 was identified as a possible new member of the TNF family. The muAGP-EST1 clone contained an 86~ bp insert with an open reading frame of about 90 amino acids which was found to have significant homology to pig lymphotoxin-~ precursor (TNF-~) and rabbit tumor necrosis factor precursor (TNF-~) (cachectin). The region compared showed an overlap of 63 amino acids and a 27% homology to TNF-~ and a 71 amino acid overlap and 30% homology to TNF-~.
Profile analysis using the TNF family profile yielded a z score of 13.5, indicating that the muAGP-EST1 clone was encoding a possible new member of the TNF family.
To obtain a full-length clone, an internal EST
database was searched for overlapping clones and two other murine EST clones were identified. One EST clone designated muAGP-EST2 from a murine irradiated small intestine library gave a sequence which overlapped the sequence obtained from the muAGP-EST1 clone. The muAGP-EST2 clone was subsequently sequenced in its entirety. The insert was 3098 bp and contained an open reading frame of 291 amino acids which was deduced to be the full-length AGP-1 sequence. The nucleotide sequence CA 022~6464 1998-11-27 W O 97t46686 PCTrUS97/098g5 and deduced amino acid of murine AGP-1 is shown in Figure 1.
B. Human AGP-1 A cDNA library was constructed using RNA from human bladder carcinoma cell line 5637 which had been stimulated with 2OnM of PMA for about nine hours. For this library, mRNA was isolated from a membrane bound polysomal fraction of RNA (Mechler Methods in Enzymology 152, 241-248 (1987)). The poly A~ mRNA
fraction was isolated from the total RNA preparation by using the Fast Track mRNA Isolation Kit (InVitrogen) according to the manufacturer's recommended procedure.
A directional random primed cDNA library was prepared essentially as described for the 5-FU mouse bone marrow library above. The cDNA inserts were sequenced as described above for the mouse cDNA clones.
The resulting 5' nucleotide sequences obtained from randomly picked cDNA clones were translated and compared to the existing database of known protein sequences using a modified version of the FASTA program (Pearson et al. ibid). Translated sequences were also analysed for the presence of specific motifs found in the tumor necrosis factor superfamily using the sequence profile method of Gribskov et.al. ibid as modified by Luethy et.al. ibid.
Using the FASTA and Profile search data, an EST from the 5637 cell line cDNA library designated huAGP-EST1 was identified as a possible new member of the TNF family. huAGP-EST1 contained an 446 bp insert with an open reading frame of about 84 amino acids.
Translation of the huAGP-EST1 nucleotide sequence gave an amino acid sequence which was 77% identical to the deduced amino acid sequence of murine AGP-1 when compared using FASTA analysis. This high degree of CA 022~6464 1998-11-27 sequence similarity identifies huAGP-EST1 as the human homolog of murine AGP-1.
To obtain a full-length clone, an internal EST
database was searched for overlapping clones and one other murine EST clone was identified. This clone, designated huAGP-EST2, was from a human peripheral blood megakaryocyte cDNA library and had an insert of 1~28 bp which overlapped the huAGP-EST1 clone. The overlapping clones had an open reading frame of 281 amino acids.
The full-length human AGP-1 was obtained as a composite of the sequences from the huAGP-EST1 and huAGP-EST2 clones. The nucleotide sequence and deduced amino acid sequence of human AGP-1 is shown in Figure 2.
Expression of AGP-1 in transgenic mice A. PCR and subcloning The TNF~-related clone muAGP-EST2 was used as template to PCR amplify the coding region for subcloning into an APOE-liver specific expression vector (Simonet et al. J. Clin. Invest. 94, 1310-1319 (1994), and PCT
Application No. WO94/11675). The oligonucleotides used for amplification were:
5'-GAC TAG TCA GAC CTG GAC AGC AGT ATG CCT TC-3' (SEQ ID NO: 12); and 5'-ATA AGA ATG CGG CCG CTA AAC TAT GGG TAC TTT AGG
GCT GTG TTT G-3' (SEQ ID NO: 13) The conditions for PCR were: 94~C for 1 minute, followed by 25 cycles of 94 C for 20 sec, 63 C
for 30 sec, and 74 C for 1 minute. The PCR reactions contained 1 x PFU buffer, 50 uM dNTPs, 20 pmol of each CA 022~6464 l998-ll-27 W O 97/46686 PCT~US97/Og895 oligo, 10 ng of DNA template and 2.5 units of PFU enzyme in a total volume of 50 ul. Following amplification, the samples were purified over Qiagen PCR columns and digested overnight with SpeI and NotI restriction enzymes. The digested products were extracted and precipitated and subcloned into the ApoE promoter expression vector.
Ligations were transformed into E. coli strain DH5a and colonies were minipreped for analysis of the insert. Two clones containing the desired size insert were grown in 100ml TB cultures and plasmid DNA was prepared. The two clones were sent to sequencing to verify the authenticity of the insert. One was selected for microinjection to generate transgenic mice. This transgene was designated HE-AGP.
B. Preparation of transgenic mice For microinjection, the HE-AGP plasmid was purified through two rounds of CsCl. The plasmid was digested with XhoI and Ase I, and the 3.9 kb transgene insert was purified on a 0.8% BRL ultrapure DNA agarose gel by electrophoresis onto NA 45 paper. The purified fragment was diluted to 1 ug/ml in 5 mM Tris, pH 7.4, 0.2 mM EDTA. Single-cell embryos from BDF1 x BDF1-bred mice were injected essentially as described (Brinster et al., 1985), except that injection needles were beveled and siliconized before use. Embryos were cultured overnight in a CO2 incubator and 15 to 20 two-cell embryos were transferred to the oviducts of pseudopregnant CD1 female mice.
C. Screening of transgenic founders Following term pregnancy, 105 offspring were obtained from implantation of microinjected embryos. Of the 105 offspring, 17 were identified as transgenic founders by screening for the HE-AGP transgene in DNA
CA 022~6464 1998-11-27 W O 97/46686 PCT~US97/09895 prepared from ear and tall biopsies. The PCR screening involved amplification of a 369 bp region of the human Apo E intron which was included in the expression vector. The oligos used for PCR amplification were:
5'-GCC TCT AGA AAG AGC TGG GAC-3' (SEQ. ID. NO: 14) 5'-CGC CGT GTT CCA TTT ATG AGC-3' (SEQ. ID. NO: 15 The conditions for PCR were: 94 C for 2 minute, followed by 30 cycles of 99 C for 1 min, 63 C
for 20 sec, and 72 C for 30 sec. The PCR reactions contained 1 x Taq buffer, 100 uM each dNTPs, 20 pmol of each oligo, 1 ul of DNA template extract and 0.5 units of taq enzyme in a total volume of 50 ul.
D. Preparation and analysis of total RNA for Northern analysis At 8-10 weeks of age, 8 of the 17 transgenics (#'s 10, 27, 52, 53, 69, 72, 76 and 77~ and 4 control littermates (#'s 55, 56, 57, and 58) were sacrificed for necropsy and pathological analysis (See Example 3).
Liver was isolated from the remaining 9 founders (#'s 25, 42, 44, 45, 48, 50, 67, 74, and 75) by partial hepatectomy. For partial hepatectomy, the mice were anesthetized with avertin and a lobe of liver was surgically removed. Total cellular RNA was isolated from livers of all transgenic founders, and 5 negative control littermates as described (McDonald et al.
(1987~). Northern blot analysis was performed on these samples to assess the level of transgene expression.
Approximately 10ug of total RNA from each animal liver was resolved by electrophoresis denaturing gels (Ogden et al. (1987)), then transferred to HYBOND-N nylon membrane (Amersham), and probed with 32p dCTP-labelled pB1.1 insert DNA. Hybridization was performed overnight at 42 C in 50% Formamide, 5 x SSPE, 0.5% SDS, 5 x CA 022~6464 l998-ll-27 W 097/46686 PCT~US97/09895 Denhardt's solution, 100 ug/ml denatured salmon sperm DNA and 2-4 x 106 cpm of labeled probe/ml of hybridization buffer. Following hybridization, blots were washed twice in 2 x SSC, 0.1% SDS at room temperature for 5 min each, and then twice in 0.1 x SSC, 0.1% SDS at 55 C for 5-10 min each. Expression of the transgene in founder and control littermates was determined following autoradiography.
The Northern blot data indicate that 13 of the transgenic founders express detectable levels of the transgene mRNA (animal #'s 10, 42, 44, 45, 4~, 50, 52, 53, 67, 69, 74, 75 and 76). The negative control mice expressed no transgene-related mRNA. The highest expressing founders From the group that were necropsied 15 were #'s 52, 69 and 76. The highest expressing animals from the remaining group of founder's were #'s 42, 45, 67, and 75. Six of the founder's that were analyzed by hepatectomy were subsequently bred to generate F1 offspring for further analysis.
Pathology Analysis of Transgenic Mice Expressing AGP-1 A. Necropsy Mice from two separate studies were examined.
In the first study, five BDF1 female mice which were founder transgenics for the murine AGP-1 molecule targeted to the liver via an apolipoprotein E promoter as well as four male non-transgenic littermate mice were necropsied for phenotypic analysis. In the second study, twelve BDF1 mice (nine females and three males) which were F1 transgenics for the murine AGP molecule targeted to the liver via an apolipoprotein E promoter as well as four female non-transgenic littermate mice CA 022~6464 l998-ll-27 were necropsied for phenotypic analysis. In both studies, all mice were injected with BrdU one hour prior to harvest and sacrificed. Body and liver, spleen, kidney, stomach, and thymus weights were taken, blood was drawn for hematology and serum chemistries, and liver, spleen, lung, brain, heart, kidney, adrenal, stomach, small intestine, pancreas, cecum, colon, mesenteric lymph node, skin, mammary gland, trachea, esophagus, thyroid, parathyroid, salivary gland, urinary bladder, ovary or testis, uterus or seminal vesicle, bone, and bone marrow were examined were harvested for histologic analysis and BrdU labeling.
B. Histology and Histochemistry Sections of liver, spleen, lung, brain, heart, kidney, adrenal, stomach, small intestine, pancreas, cecum, colon, mesenteric lymph node, skin, mammary gland, trachea, esophagus, thyroid, parathyroid, salivary gland, urinary bladder, ovary or testis, uterus or seminal vesicle, bone, and bone marrow from AGP-1 transgenic and non-transgenic mice were fixed overnight in 10% neutral buffered zinc formalin (Anatech, Battle Creek, Michigan), paraffin embedded, sectioned at 3 ,um, and stained with hematoxylin and eosin (H&E) for routine histologic examination. In addition, sections of bone were stained for tartrate resistant acid phosphatase (TRAP) to highlight osteoclasts around bony trabeculae ln marrow spaces.
C. Immunohistochemistry Immunohistochemical staining was done on 9 ~m thick paraffin embedded sections using an automated TechMate Immunostainer (BioTek Solutions, Santa Barbara, CA). For BrdlJ immunostaining, sections were first digested with 0.1% protease (Sigma Chemical, St. ~ouis, MO) followed by 2N HCl. BrdU was detected with a rat CA 022~6464 1998-11-27 monoclonal antibody (MAb) to BrdU (Accurate Chemical, Westbury, NY) followed by a biotinylated anti-rabbit/anti-mouse secondary cocktail (BioTek) and an ABC tertiary coupled to alkaline phosphatase (BioTek). The staining reaction was visualized with BioTek Red chromagen (BioTek). For myeloperoxidase immunostaining, sections were stained with rabbit polyclonal antisera directed at human myeloperoxidase (Dako, Carpinteria, CA), followed by a biotinylated anti-rabbit/anti-mouse secondary cocktail (BioTek) and avidin-biotin complex (ABC) tertiary coupled to horseradish peroxidase. The staining reaction was visualized with diaminobenzidine (DAB, Sigma).
D. GroQ~ Pathology FindingQ
The livers from two transgenic founder mice(#s 69 and 76) and two F1 transgenic mice (#s 75-13 and 75-18) were significantly increased in size and weight (8.42 + 1.26 SD % of body weight vs. 5.33 +
0.89 SD % of body weight in non-transgenic control mice) and were pale green-tan and more friable than normal.
These four mice also had a significant increase in splenic weight (1.14 + 0.12 SD % of body weigh~ vs. 0.41 ~ 0.09 SD ~ body weight in non-transgenic control mice.
These results are summarized in Table 1.
E. Clinical Pathology Findings The four transgenic mice with enlarged livers (founder #s 69 and 76 and F1 #s 75-13 and 75-18 had marked and significant increases in total serum bilirubin and alkaline phosphatase levels, with moderate bu~ significant increases in hepatic transaminase (alanine aminotrans~erase (ALT) and aspartate aminotransferase (AST)) levels. The four transgenic mice had a mean total bilirubin level of 4.33 i 5.32 SD mg/dl while non-transgenic control mice had a CA 022~6464 1998-11-27 W O 97/46686 PCTrUS97/09895 mean total bilirubin level of 0.16 + 0.05 SD mg/dl. The mean serum alkaline phosphatase level in these four transgenic mice was 994.5 + 353.1 SD IU/l vs. 165.3 +
53.2 SD IU/l in non-transgenic control mice. The mean ALT level in these four transgenic mice was 247.3 + 89.8 SD IU/l vs. 7~.1 + 43.2 SD IU/l in non-transgenic control mice while the mean AST level in these four transgenic mice was 350.5 + 135.6 SD IU/1 vs. 132.5 +
84.9 SD IU/l in non-transgenic control mice. All of these results are summarized in table 1.
F. Histopathologic Findings H&E and BrdU stained sections of liver, spleen, lung, brain, heart, kidney, adrenal, stomach, small intestine, pancreas, cecum, colon, mesenteric lymph node, skin, mammary gland, trachea, esophagus, thyroid, parathyroid, salivary gland, urinary bladder, ovary or testis, uterus or seminal vesicle, bone, and bone marrow were examined from the 17 HE-AGP-l transgenic mice and 8 non-transgenic control littermates. Myeloperoxidase stained sections of spleen and bone marrow as well as tartrate resistant acid phosphatase (TRAP) stained sections of bone were also examined from all mice. Major histologic changes in the transgenic mice included marked periportal inflammation and bile duct hyperplasia with scattered multifocal to coalescing areas of hepatocellular necrosis in transgenic mice #s 69 and 76 (founders) and #s 75-13 and 75-18 (Fls) (Figure 3). All four of these transgenic mice also had enlarged spleens primarily due to increased red pulp myelopoiesis and to a lesser extent, lymphoid hyperplasia (Figure 4). These four transgenic mice also appeared to have increased numbers of TRAP
positive osteoclasts lining bony trabeculae in peripheral diaphyseal marrow compared to non-transgenic control mice ~Figure 5). Transgenic mice also exhibited CA 022~6464 1998-11-27 W O 97/46686 PCT~US97/09895 increased intravascular neutrophils, and small atrophic/hypoplastic uteri (only founder transgenics #s 69 and 76). The two founder transgenic mice (#s 69 and 76) also exhibited moderate peritoneal mixed inflammatory cellular infiltration.
G. Summary of Pathologic Findings in Transgenic Mice Overexpressing AGP-1 Four of the HE-AGP-1 transgenic mice (founder nos. 69 and 76 and F1 nos. 75-13 and 75-18) had relatively severe phenotypic alterations, particularly in their livers with marked cholangiohepatitis, bile duct hyperplasia and hepatic necrosis. Accompanying these hepatic histologic abnormalities in these four transgenic mice was evidence of liver dysfunction with marked elevations in total serum bilirubin and alkaline phosphatase with moderate elevations in serum transaminases. In addition to hepatic findings, these four transgenic mice also exhibited increased myelopoiesis, with a less prominent increase in circulating platelets. Founder mouse #69 had a circulating neutrophilia while all transgenic mice had a moderate increase in circulating lymphocytes. Evidence of peritoneal inflammation was also seen in the two founder transgenic mice with marked hepatic inflammation. Two of the other ~EAGP founder transgenic mice, #'s 52 and 53, also had evidence of mild cholangiohepatitis, and a mild to moderate increase in myelopoiesis and neutrophilia, suggesting that these two mice were producing the transgenic AGP-1 protein at a lower level than founder mice #s 69 and 76 were. In addition to hepatic findings, at least four of the transgenic mice exhibited a marked increase in splenic myelopoiesis and moderate lymphoid hyperplasia as well as exhibiting an apparent increase in TRAP+ osteoclasts lining bony trabeculae in the bone marrow. All of these .
findings suggest that the AGP protein plays a role in inflammation, myelopoiesis, and bone resorption (osteoclasis).
Table 1 Selected Organ Weight~ and Serum Chemi~trie~ in HE-AGP-1 Tran~genic Mice HEAGP Non- p value Transgenic transgenic Mice ~n=4) Mice (n=8) Li~er Weight as 8.42 + 1.26 SD 5.33 + 0.89 0.0006 % of Body Weight SD
Spleen Weight as 1.14 + 0.12 SD 0.41 + 0.09 <0.0001 % Body Weight SD
Total Bilirubin 4.33 + 5.32 SD 0.16 + 0.05 0.04 (mg/dl) SD
Alkaline 994.5 + 353.1 165.3 + 53.2 <0.0001 Phosphatase SD SD
(IU/l) Alanine 247.3 + 89.8 SD 78.1 + 43.2 0.001 Aminotran~ferase SD
~ALT) (IU/l) Aspartate 350.5 + 135.6 132.5 + 84.9 0.006 Aminotransferase SD SD
(AST) (IU/l) CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 SEQUENCE LISTING
(1) GENERAL INFORMATION:
~i) APPLICANT: Johnson, Merrie Jo Simonet, William S.
Danilenko, Dimitry M.
(ii) TITLE OF INVENTION: TUMOR NECROSIS FACTOR-RELATED
POLYPEPTIDE
(iii) NUMBER OF SEQUENCES: 15 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Amgen Inc.
(B) STREET: 1840 Dehavilland Drive (C) CITY: Thousand Oaks (D) STATE: California (E) COUNTRY: U.S.A.
(F) ZIP: 91320 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Winter, Robert B.
(C) REFERENCE/DOCKET NUMBER: A-410 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3048 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 245..1120 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 ~ 31 -GACCl-ClCA GGCACTGCTG CTGGGCTGCA AGTCTGCATT GGGAAGTCAG ACCTGGACAG 240 Met Pro Ser Ser Gly Ala Leu Lys Asp Leu Ser Phe Ser Gln His Phe Arg Met Met Val Ile Cys Ile Val Leu Leu Gln Val Leu Leu Gln Ala Val Ser Val Ala Val Thr Tyr Met Tyr Phe Thr Asn Glu Met Lys 20 Gln Leu Gln Asp Asn Tyr Ser Lys Ile Gly Leu Ala Cys Phe Ser Lys Thr Asp Glu Asp Phe Trp Asp Ser Thr Asp Gly Glu Ile Leu Asn Arg Pro Cys Leu Gln Val Lys Arg Gln Leu Tyr Gln Leu Ile Glu Glu Val Thr Leu Arg Thr Phe Gln Asp Thr Ile Ser Thr Val Pro Glu Lys Gln Leu Ser Thr Pro Pro Leu Pro Arg Gly Gly Arg Pro Gln Lys Val Ala 40 Ala His Ile Thr Gly Ile Thr Arg Arg Ser Asn Ser Ala Leu Ile Pro Ile Ser Lys Asp Gly Lys Thr Leu Gly Gln Lys Ile Glu Ser Trp Glu Ser Ser Arg Lys Gly His Ser Phe Leu Asn His Val Leu Phe Arg Asn Gly Glu Leu Val Ile Glu Gln Glu Gly Leu Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe Gln Glu Ala Glu Asp Ala Ser Lys Met Val Ser CA 022~6464 1998-11-27 W 0 97/46686 PCTrUS97/09895 Lys Asp Lys Val Arg Thr Lys Gln Leu Val Gln Tyr Ile Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Val Leu Met Lys Ser Ala Arg Asn Ser 0 Cys Trp Ser Arg Asp Ala Glu Tyr Gly Leu Tyr Ser Ile Tyr Gln Gly Gly Leu Phe Glu Leu Lys Lys Asn Asp Arg Ile Phe Val Ser Val Thr Asn Glu His Leu Met Asp Leu Asp Gln Glu Ala Ser Phe Phe Gly Ala Phe Leu Ile Asn *
CA 022~6464 l998-ll-27 TCCACCTACC AAGATGTTGA ACA~ C TTTTTAAGAT ~1lGG1GCCl GGAGTTTCAT 2360 TAGAGTAACA CAAAACTAAC TAAAACCAAA CAACTCCAAA GGAGCCCATA TGIGl.l.AA 2420 TGAAACATTT TTTAAGCCTA TTGGGGGCCT ~AAGAGATTG CTCAGAGGAA AACAGCACTT 2480 CATTCTGACA AAATATATCC ATACACAAAA GTA~ l AAAAGCTTAT TTGAATGTAA 2660 ~2) INFORMATION FOR SEQ ID No:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 292 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Met Pro Ser Ser Gly Ala Leu Lys Asp Leu Ser Phe Ser Gln His Phe Arg Met Met Val Ile Cys Ile Val Leu Leu Gln Val Leu Leu Gln Ala Val Ser Val Ala Val Thr Tyr Met Tyr Phe Thr Asn Glu Met Lys Gln Leu Gln Asp Asn Tyr Ser Lys Ile Gly Leu Ala Cys Phe Ser Lys Thr Asp Glu Asp Phe Trp Asp Ser Thr Asp Gly Glu Ile Leu Asn Arg Pro CA 022~6464 l998-ll-27 ~ 39 -Cys Leu Gln Val Lys Arg Gln Leu Tyr Gln Leu Ile Glu Glu Val Thr Leu Arg Thr Phe Gln Asp Thr Ile Ser Thr Val Pro Glu Lys Gln Leu Ser Thr Pro Pro Leu Pro Arg Gly Gly Arg Pro Gln Lys Val Ala Ala His Ile Thr Gly Ile Thr Arg Arg Ser Asn Ser Ala Leu Ile Pro Ile Ser Lys Asp Gly Lys Thr Leu Gly Gln Lys Ile Glu Ser Trp Glu Ser Ser Arg Lys Gly His Ser Phe Leu Asn His Val Leu Phe Arg Asn Gly Glu Leu Val Ile Glu Gln Glu Gly Leu Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe Gln Glu Ala Glu Asp Ala Ser Lys Met Val Ser Lys Asp Lys Val Arg Thr Lys Gln Leu Val Gln Tyr Ile Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Val Leu Met Lys Ser Ala Arg Asn Ser Cys Trp Ser Arg Asp Ala Glu Tyr Gly Leu Tyr Ser Ile Tyr Gln Gly Gly Leu Phe Glu Leu Lys Lys Asn Asp Arg Ile Phe Val Ser Val Thr Asn Glu His Leu Met Asp Leu Asp Gln Glu Ala Ser Phe Phe Gly Ala Phe Leu Ile Asn *
(2) INFORMATION FOR SEQ ID NO:3:
~i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1060 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 35..880 CA 022~6464 l998-ll-27 W O 97/46686 PCT~US97/09895 ~xi) SL~UENCE DESCRIPTION: SEQ ID NO:3:
Met Ala Met Met Glu Val Gln Gly Gly Pro Ser Leu Gly Gln Thr Cys Val Leu Ile Val Ile Phe Thr Val Leu Leu Gln Ser Leu Cys Val Ala Val Thr Tyr Val Tyr Phe Thr Asn Glu Leu Lys Gln Met Gln Asp Lys Tyr Ser Lys Ser Gly Ile 20 Ala Cys Phe Leu Lys Glu Asp Asp Ser Tyr Trp Asp Pro Asn Asp Glu Glu Ser Met Asn Ser Pro Cys Trp Gln Val Lys Trp Gln Leu Arg Gln Leu Val Arg Lys Met Ile Leu Arg Thr Ser Glu Glu Thr Ile Ser Thr Val Gln Glu Lys Gln Gln Asn Ile Ser Pro Leu Val Arg Glu Arg Gly Pro Gln Arg Val Ala Ala His Ile Thr Gly Thr Arg Gly Arg Ser Asn 40 Thr Leu Ser Ser Pro Asn Ser Lys Asn Glu Lys Ala Leu Gly Arg Lys Ile Asn Ser Trp Glu Ser Ser Arg Ser Gly His Ser Phe Leu Ser Asn Leu His Leu Arg Asn Gly Glu Leu Val Ile His Glu Lys Gly Phe Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe Gln Glu Glu Ile Lys Glu Asn Thr Lys Asn Asp Lys Gln Met Val Gln Tyr Ile Tyr Lys Tyr Thr CA 022~6464 l998-ll-27 W O 97/46686 PCT~US97/09895 Ser Tyr Pro Asp Pro Ile Leu Leu Met Lys Ser Ala Arg Asn Ser Cys Trp Ser Lys Asp Ala Glu Tyr Gly Leu Tyr Ser Ile Tyr Gln Gly Gly 10 Ile Phe Glu Leu Lys Glu Asn Asp Arg Ile Phe Val Ser Val Thr Asn Glu His Leu Ile Asp Met Asp His Glu Ala Ser Phe Phe Gly Ala Phe Leu Val Gly *
CAGAAAACAG AAAACAAAAA AACCTCTATG CAATCTGAGT AGAGCAGCcA CAACCAAAAT 1040 (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 282 amino acids (L) TYPE: amino acid ~D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Met Ala Met Met Glu Val Gln Gly Gly Pro Ser Leu Gly Gln Thr Cys Val Leu Ile Val Ile Phe Thr Val Leu Leu Gln Ser Leu Cys Val Ala Val Thr Tyr Val Tyr Phe Thr Asn Glu Leu Lys Gln Met Gln Asp Lys Tyr Ser Lys Ser Gly Ile Ala Cys Phe Leu Lys Glu Asp Asp Ser Tyr Trp Asp Pro Asn Asp Glu Glu Ser Met Asn Ser Pro Cys Trp Gln Val Lys Trp Gln Leu Arg Gln Leu Val Arg Lys Met Ile Leu Arg Thr Ser Glu Glu Thr Ile Ser Thr Val Gln Glu Lys Gln Gln Asn Ile Ser Pro CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 ~ 37 -Leu Val Arg Glu Arg Gly Pro Gln Arg Val Ala Ala His Ile Thr Gly 5 Thr Arg Gly Arg Ser Asn Thr Leu Ser Ser Pro Asn Ser Lys Asn Glu Lys Ala Leu Gly Arg Lys Ile Asn Ser Trp Glu Ser Ser Arg Ser Gly His Ser Phe Leu Ser Asn Leu His Leu Arg Asn Gly Glu Leu Val Ile His Glu Lys Gly Phe Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe Gln Glu Glu Ile Lys Glu Asn Thr Lys Asn Asp Lys Gln Met Val Gln Tyr Ile Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Leu Leu Met Lys Ser Ala Arg Asn Ser Cys Trp Ser Lys Asp Ala Glu Tyr Gly Leu Tyr Ser Ile Tyr Gln Gly Gly Ile Phe Glu Leu Lys Glu Asn Asp Arg Ile Phe Val Ser Val Thr Asn Glu His Leu Ile Asp Met Asp His Glu Ala Ser Phe Phe Gly Ala Phe Leu Val Gly *
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear CA 022~6464 l998-ll-27 W O 97/46686 PCTrUS97/09895 (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
~A) LENGTH: 12 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: slngle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
CGGACGCGTG GG
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
CA 022~6464 l998-ll-27 W O 97/46686 P ~ rusg7/og895 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
(2) INFORMATION FOR SEQ ID NO:ll:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TopoLoGy: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:ll:
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
CA 022~6464 l998-ll-27 ~2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
(2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
Claims (33)
1. An isolated nucleic acid encoding a polypeptide comprising at least one of the biological activities of AGP-1 wherein the nucleic acid is selected from the group consisting of:
a) the nucleic acids shown in Figure 1 (SEQ ID
NO: 1) or Figure 2 (SEQ ID NO: 3);
b) nucleic acids which hybridize to the polypeptide coding regions of the nucleic acids shown in Figure 1 (SEQ ID NO: 1) or Figure 2 (SEQ ID NO: 3) and remain hybridized to the nucleic acids under high stringency conditions; and c) nucleic acids which are degenerate to the nucleic acids of (a) or (b).
a) the nucleic acids shown in Figure 1 (SEQ ID
NO: 1) or Figure 2 (SEQ ID NO: 3);
b) nucleic acids which hybridize to the polypeptide coding regions of the nucleic acids shown in Figure 1 (SEQ ID NO: 1) or Figure 2 (SEQ ID NO: 3) and remain hybridized to the nucleic acids under high stringency conditions; and c) nucleic acids which are degenerate to the nucleic acids of (a) or (b).
2. The nucleic acid of Claim 1 which is cDNA, genomic DNA, synthetic DNA or RNA.
3. A polypeptide encoded by the nucleic acid of Claim 1.
4. The nucleic acid of Claim 1 including one or more codons preferred for Escherichia coli expression.
5. The nucleic acid of Claim 1 having a detectable label attached thereto.
6. The nucleic acid of Claim 1 comprising the polypeptide-coding region of Figure 2 (SEQ ID NO: 3).
7. A nucleic acid encoding a polypeptide having the amino acid sequence of SEQ. ID. NO. 2 or SEQ.
ID. NO. 4.
ID. NO. 4.
8. An expression vector comprising the nucleic acid of Claim 1.
9. The expression vector of Claim 8 wherein the nucleic acid comprises the polypeptide-encoding region as shown in Figure 1 (SEQ ID NO: 1) or Figure 2 (SEQ ID NO: 3).
10. A host cell transformed or transfected with the expression vector of Claim 8.
11. The host cell of Claim 10 which is a eucaryotic or procaryotic cell.
12. The host cell of Claim 11 which is Escherichia coli.
13. A process for the production of AGP-1 comprising:
growing under suitable nutrient conditions host cells transformed or transfected with the nucleic acid of Claim 1; and isolating the polypeptide product of the expression of the nucleic acid.
growing under suitable nutrient conditions host cells transformed or transfected with the nucleic acid of Claim 1; and isolating the polypeptide product of the expression of the nucleic acid.
14. A polypeptide produced by the process of Claim 13.
15. A purified and isolated AGP-1 polypeptide.
16. The polypeptide of Claim 15 which is mammalian AGP-1.
17. The polypeptide of Claim 15 having the amino acid sequence as shown in Figure 2 (SEQ ID NO: 3).
18. The polypeptide of Claim 17 which has been covalently modified with a water-soluble polymer.
19. The polypeptide of Claim 18 wherein the polymer is polyethylene glycol.
20. An antibody or fragment thereof which specifically binds AGP-1.
21. The antibody of Claim 20 which is a monoclonal antibody.
22. A method for detecting the presence of AGP-1 in a biological sample comprising:
incubating the sample with the antibody of Claim 20 under conditions that allow binding of the antiboby to AGP-1; and detecting the bound antibody.
incubating the sample with the antibody of Claim 20 under conditions that allow binding of the antiboby to AGP-1; and detecting the bound antibody.
23. A method to assess the ability of a candidate compound to bind AGP-1 comprising:
incubating AGP-1 with the candidate compound under conditions that allow binding; and measuring the bound compound.
incubating AGP-1 with the candidate compound under conditions that allow binding; and measuring the bound compound.
24. The method of Claim 23 wherein the compound is an antagonist of AGP-1.
25. A method of regulating expression of AGP-1 in an animal comprising administering to the animal a nucleic acid complementary to the nucleic acids as shown in Figure 1 (SEQ ID NO: 1) or Figure 2 (SEQ ID NO: 3) .
26. A pharmaceutical composition comprising a therapeutically effective amount of AGP-1 in a pharmaceutically acceptable carrier, adjuvant, solubilizer, stabilizer and/or anti-oxidant.
27. The composition of Claim 26 wherein AGP-1 is human AGP-1.
28. A method of treating an inflammatory disorder comprising administering a therapeutically effetive amount of an AGP-1 antagonist.
29. The method of Claim 28 further comprising administering a therapeutically effective amount of an anti-inflammatory agent selected from the group consisting of a corticosteroid, a non-steroidal anti-inflammatory agent, and a cyclosporin.
30. A method of treating a hematopoietic disorder comprising adminstering a therapeutically effective amount of AGP-1.
31. The method of Claim 30 further comprising administering a therapeutically effective amount of a hematopoietic factor selected from the group consisting of EPO. G-CSF, MGDF, GM-CSF, SCF, IL-3 and IL-6.
32. A method of treating a bone disorder comprising administering a therapeutically effective amount of an AGP-1 antagonist.
33. The method of Claim 31 further comprising administering a therapeutically effective amount of a bone growth factor selected from the group consisting of: bone morphogenic factors BMP-1 to BMP-12, TGF-.beta.
family members, IL-1 inhibitors, TNF.alpha.. inhibitors, parathyroid hormone, E series prostaglandins, bisphosphonates and bone-enhancing minerals.
family members, IL-1 inhibitors, TNF.alpha.. inhibitors, parathyroid hormone, E series prostaglandins, bisphosphonates and bone-enhancing minerals.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66056296A | 1996-06-07 | 1996-06-07 | |
US08/660,562 | 1996-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2256464A1 true CA2256464A1 (en) | 1997-12-11 |
Family
ID=24650031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002256464A Abandoned CA2256464A1 (en) | 1996-06-07 | 1997-06-06 | Tumor necrosis factor-related polypeptide |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0918860A2 (en) |
JP (1) | JP2000515727A (en) |
AU (1) | AU3381097A (en) |
CA (1) | CA2256464A1 (en) |
WO (1) | WO1997046686A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
US5763223A (en) * | 1995-06-29 | 1998-06-09 | Immunex Corporation | DNA encoding a cytokine that induces apoptosis |
US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
US6046048A (en) * | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
FR2766713B1 (en) * | 1997-08-04 | 1999-09-24 | Bio Merieux | PROTEIN FACTOR ASSOCIATED WITH NEURO-DEGENERATIVE AND / OR AUTOIMMUNE AND / OR INFLAMMATORY DISEASE |
AU2325199A (en) | 1998-01-15 | 1999-08-02 | Genentech Inc. | Apo-2 ligand |
EP1941905A1 (en) | 1998-03-27 | 2008-07-09 | Genentech, Inc. | APO-2 Ligand-anti-her-2 antibody synergism |
WO2000047740A2 (en) * | 1999-02-12 | 2000-08-17 | Amgen Inc. | Tnf-related proteins |
WO2000063253A1 (en) * | 1999-04-16 | 2000-10-26 | Amgen Inc. | Agp-1 fusion protein compositions and methods |
EP1870464A3 (en) * | 1999-06-02 | 2008-03-12 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
NZ537920A (en) | 1999-06-28 | 2006-10-27 | Genentech Inc | An isolated Apo-2 ligand variant polypeptide comprising an amino acid sequence which differs from the native sequence Apo-2 ligand |
DK1303293T3 (en) | 2000-07-27 | 2009-03-30 | Genentech Inc | Sequential administration of CPT-11 and APO-2L polypeptide |
DE102006017226A1 (en) * | 2006-04-12 | 2007-10-18 | Schaeffler Kg | Guide carriage roller for linear guide roller, has inner ring provided with depression to receive screw head, where countersunk head of countersunk screw is absorbed in conical depression |
RU2609871C1 (en) * | 2015-08-10 | 2017-02-06 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Antitumor agent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US5763223A (en) * | 1995-06-29 | 1998-06-09 | Immunex Corporation | DNA encoding a cytokine that induces apoptosis |
US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
-
1997
- 1997-06-06 AU AU33810/97A patent/AU3381097A/en not_active Abandoned
- 1997-06-06 EP EP97929846A patent/EP0918860A2/en not_active Withdrawn
- 1997-06-06 JP JP10500892A patent/JP2000515727A/en active Pending
- 1997-06-06 CA CA002256464A patent/CA2256464A1/en not_active Abandoned
- 1997-06-06 WO PCT/US1997/009895 patent/WO1997046686A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1997046686A3 (en) | 2001-06-28 |
EP0918860A2 (en) | 1999-06-02 |
WO1997046686A2 (en) | 1997-12-11 |
JP2000515727A (en) | 2000-11-28 |
AU3381097A (en) | 1998-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6284740B1 (en) | Osteoprotegerin | |
Gross et al. | TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS | |
US7923008B2 (en) | Methods for decreasing osteoclast formation or bone resorption using an antibody to osteoprotegerin binding protein | |
AU710587B2 (en) | Osteoprotegerin | |
US7473765B2 (en) | Cytokine zalpha11 ligand | |
EP1997512B1 (en) | Methods for treating TWEAK-related conditions | |
CA2256464A1 (en) | Tumor necrosis factor-related polypeptide | |
PT1009832E (en) | Cytokine designated lerk-6 | |
WO1997046686A9 (en) | Tumor necrosis factor-related polypeptide | |
PL207501B1 (en) | Baff receptor (bcma), an immunoregulatory agent | |
US20030207827A1 (en) | Osteoprotegerin | |
EP0877803B1 (en) | Ob protein receptor and related compositions and methods | |
WO2000034475A2 (en) | Grnf4, a gdnf-related neurotrophic factor | |
WO2003102199A1 (en) | New gdf-9 and gdf-9b (bmp-15) sequences for altering mammalian ovarian function and ovulation rate | |
US5684222A (en) | Mutant mouse having a disrupted TNFRp55 | |
US20060078550A1 (en) | Porcine fgl2 | |
MXPA98010205A (en) | Tumor necrosis factor related polypeptide | |
AU758672B2 (en) | Osteoprotegerin | |
JP2001505420A (en) | Liver activin / inhibin nucleotide and protein sequences and methods based thereon | |
Zhou | Targeted disruption of the mouse growth hormone receptor/binding protein gene by homologous recombination | |
CA2203706A1 (en) | Human jak2 kinase | |
JP2003532406A (en) | Fusion receptor derived from TNF family |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |